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Zusammenfassung  
Malaria ist eine Infektionskrankheit von globaler Bedeutung an der jährlich etwa eine 
halbe Millionen Menschen sterben. Die sexuellen Stadien (Gametozyten) sind 
verantwortlich für die Transmission des Parasiten von dem humanen Zwischenwirt 
auf den Mückenvektor. Trotz ihrer Bedeutung für die Transmission und damit für die 
Aufrechterhaltung des Zyklus ist weder ein sicheres und hocheffektives Medikament 
noch ein transmissionblockierender Impfstoff gegen plasmodiale Gametozyten 
erhältlich, auch nicht gegen Plasmodium falciparum - die medizinisch bedeutenste 
Plasmodienspezies. Darüber hinaus ist nur sehr wenig bekannt über die Biologie 
dieses Parasitenstadiums, seine Medikamentensensitivität, seine Langlebigkeit und 
die Erkennung durch das Immunsystem.  
 
Im Rahmen dieser Arbeit wurden die Lebensdauer von P. falciparum Gametozyten 
und die natürliche Antikörperantwort auf reife Gametozyten systematisch untersucht. 
Zusätzlich wurde die Aktivität von neuen Substanzen auf reife Gametozyten 
evaluiert. Bisher wurde die Lebensdauer von P. falciparum Gametozyten in vivo nur 
geschätzt, meistens durch mathematische Modellierungen. Hier wurde zum ersten 
Mal die Lebensdauer von Gametozyten in vitro durch das Messen der Viabilität von 
Parasiten in der Gametozytenkultur für einen längeren Zeitraum gemessen. Es 
konnte mit verschiedenen Viabilitätsassays beobachtet werden, dass reife 
Gametozyten für ein Maximum von 16 bis 32 Tagen ab dem Tag der Reife (in vivo 
Zirkulationszeit) mit einer durchschnittlichen Halbwertszeit von 2,6 bis 6,5 Tage 
überleben. Zusätzlich konnte beobachtet werden, dass reife männliche Gametozyten 
für 2 Wochen exflagellieren konnten, dies zeigt ihre Viabilität und ihre nach wie vor 
vorhandene potentielle Fähigkeit Mücken zu infizieren.  
 
Die natürlich erworbene Antikörperantwort gegenüber Gametozyten wurde ebenfalls 
in einem klinischen Umfeld untersucht. Wie erwartet war die Antikörpererkennung 
nach Fixierung und Permeabilisierung der mit Gametozyten infizierten Erythrozyten 
erhöht. Die Erkennung des Laborstamms NF54 und des klinischen Isolats JH013 
durch Antikörper war ähnlich. Erwachsene zeigten eine stärkere Antikörperantwort 
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und höhere Seroprävalenz verglichen mit Kindern. Eine signifikant schwächere 
Antikörperantwort wurde in Erwachsenen (nicht aber in Kindern), die mit dem 
Malariaimpfstoff-Kandidaten GMZ2 geimpft wurden, beobachtet, wenn Tag 84 mit 
Baseline verglichen wurde. Die Untersuchung der Zusammenhänge zwischen den 
Antikörpern gegen Gametozyten und der Antikörperantwort gegen alle asexuellen 
Antigene zeigte eine positive Korrelation in Erwachsenen; diese Korrelation war bei 
Kindern nicht nachweisbar. Die Ergebnisse zeigten auch, dass Kinder, die mit 
intestinalen Helminthen (Ascaris) infiziert waren, eine signifikant höhere 
Antikörperantwort gegen Gametozyten aufwiesen als nicht infizierte Kinder.  
 
Zusätzlich wurde die Sensitivität reifer Gametozyten gegen neue Substanzen 
untersucht. Hierfür wurde die Aktivität von synthetisch hergestellten Farbstoffen 
gegen reife Gametozyten getestet. Fünf Fluoreszenzfarbstoffe zeigten eine Aktivität 
bei einer submikromolaren Konzentration gegen reife P. falciparum Gametozyten 
des kulturadaptierten 3D7 Stamms und gegen zwei klinische Isolate. 3D7 war 
sensitiver als die klinischen Isolate. Drei mitochondriale Farbstoffe (MitoRed, DiOC6 
und Rhodamine B) zeigten mit der 50% inhibitorischer Konzentration (IC50) von 
unter 200 nM sogar eine noch höhere Aktivität als der Kontrollfarbstoff Methylenblau 
(770 nM), von dem bekannt ist, dass er antigametozytär wirkt. Unter den drei 
Farbstoffen war MitoRed am aktivsten sowohl gegen 3D7 als auch gegen die 
klinischen Isolate, mit einer 3-fachen höheren Inhibition nach einer Inkubationszeit 
von 48 h verglichen mit 24 h. Der Effekt der Inkubationszeit auf die Aktivität von 
Medikamenten wurde auch bei den Kontrollmedikamenten Epoxomicin und 
Artesunate beobachtet.  
 
In einem weiteren Projekt, wurde der antigametozytäre Effekt von einer neuen 
Substanz aus Myxobakterien, Chlorotonil A untersucht. Reife Gametozyten 
reagierten sensitiv auf Chlorotonil A bei einer geringen nanomolaren Konzentration, 
ähnlich der Konzentration die Aktivität gegen asexuellen Blutparasitenstadien zeigt, 
und ist damit besser als die meisten anderen Malariamedikamente, die momentan in 
der Entwicklung sind. Dies unterstreicht das Potential von Chlorotonil A als einen 
Kandidaten für die weitere Medikamentenentwicklung. 
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Allgemein wurde in dieser PhD Arbeit gezeigt, dass reife P. falciparum Gametozyten 
2-4 Wochen in vitro überleben. Dies ermöglicht eine Einschätzung der in vivo 
Zirkulationszeit, welche für die Modellierung der Transmission und den Effekt von 
transmissionsblockierenden Maßnahmen verwendet werden kann. Diese 
Maßnahmen könnten entweder immunologisch oder medikamentenbasiert sein. Im 
zweiten Teil der Untersuchungen wurde gezeigt, dass die natürlich erworbenen 
Antikörper gegen die Oberflächenantigene von Erythrozyten, die mit Gametozyten 
infiziert sind, beeinflusst werden durch Impfung und Koinfektion mit Helminthen. In 
einem dritten und vierten Teilprojekt, zeigte das Screening von Substanzen, dass 
mitochondriale Fluoreszenzfarbstoffe und Chlorotonil A eine hohe inhibitorische 
Aktivität gegen reife P. falciparum Gametozyten haben und damit interessant für die 
klinische Entwickung sind. 
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Summary  
Malaria is an infectious disease of global health importance with approximately half a 
million global annual deaths. The sexual forms (gametocytes) are responsible for 
transmission of the malaria parasite Plasmodium from the human host to the 
mosquito vector. Despite their importance for transmission and therefore 
maintenance of the cycle, no safe and highly effective drug nor a transmission 
blocking vaccine against Plasmodium gametocytes including P. falciparum, the most 
important plasmodial species, are available. In addition, only little is known about the 
biology, susceptibility, longevity and recognition by the immune system of these 
essential stages. In this PhD work, the lifespan of P. falciparum gametocytes and 
natural antibody response to late-stage gametocytes were systematically 
investigated. Additionally, susceptibility of mature gametocytes to new compounds 
was evaluated. 
 
Previously, P. falciparum gametocyte lifespan was estimated in vivo; mostly by 
mathematical modelling. Here, longevity of gametocytes was measured for the first 
time in vitro by measuring parasite viability in gametocyte culture for an extended 
period. It was observed that mature gametocytes can survive a maximum of 16-32 
days from the day of maturation (representing the in vivo circulation time) with an 
average half-life of 2.6 to 6.5 days as evaluated by the different viability assays. In 
addition, mature male gametocytes were found to be able to exflagellate for two 
weeks, which shows their viability and sustained potential capability to infect 
mosquitoes.  
 
In line with this, the naturally acquired antibody (Ab) response towards gametocytes 
was also explored in clinical settings. As expected, Ab recognition increased after 
fixation and permeabilization of gametocyte-infected erythrocytes. Ab recognition 
between the laboratory strain (NF54) and a clinical isolate (JH013) was similar. 
Adults showed a higher Ab response and sero-prevalence compared to children. A 
significant lower level of Ab response was observed in adults vaccinated with the 
malaria vaccine candidate GMZ2 (but not in children) after 84 days compared to 
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baseline. When testing the association between the anti-gametocyte Ab response to 
the Ab response to whole asexual antigens, a positive correlation was observed in 
adults but not in children. The evaluation of the effect of intestinal helminths infection 
showed that children infected with Ascaris had a significantly higher anti-gametocyte 
Ab response compared to uninfected children.  
 
Additionally, to evaluate the sensitivity of mature gametocytes to new compounds, 
activity of synthetic dyes was tested against mature gametocytes. Five fluorescent 
dyes showed activity at submicromolar concentration against P. falciparum mature 
gametocytes of the culture-adapted 3D7 clone and two clinical isolates. 3D7 was 
observed to be more sensitive than the clinical isolates. Three mitochondrial dyes 
(MitoRed, DiOC6, and rhodamine B) were even more active, with 50% inhibitory 
concentrations (IC50s) below 200nM, than the control dye methylene blue (770nM) 
that is known to have gametocidal activity. Among the three, MitoRed was most 
active against 3D7 and clinical isolates, with a 3-fold higher inhibition when 
incubated for 48h than for 24h. The effect of incubation time on the activity of drugs 
was also pronounced with the control drugs, epoxomicin and artesunate.  
 
In a different project, the gametocidal effect of a new myxobacterial compound, 
chlorotonil A, was investigated. Mature gametocytes were sensitive to chlorotonil A 
at a low nanomolar concentration, which is similar to its activity against asexual 
blood stage parasites and superior to most other antimalarials in development. This 
underlines the potential of chlorotonil A as a drug development candidate.  
 
Altogether in this PhD work, it was shown that P. falciparum gametocytes survive in 
vitro 2-4 weeks after maturation. This provides an estimate of the in vivo circulation 
time that can be used to model transmission and the effect of transmission-blocking 
interventions. These interventions could be immunological or drug-mediated. The 
second set of investigations showed that naturally acquired antibodies against 
gametocyte-infected erythrocyte surface antigens were affected by vaccination and 
helminth co-infections. In the third and fourth subproject, screening of compounds 
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showed that mitochondrial fluorescent dyes and chlorotonil A had high inhibitory 
activity against P. falciparum mature gametocytes and may be developed further. 
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1 General introduction and background 
1.1 Malaria: global distribution and clinical burden 
Malaria is a preventable and treatable disease that is transmitted by female 
Anopheles mosquitoes as vector. The disease is of global health importance 
especially in sub-Saharan Africa (Figure 1). According to current estimates, 
approximately 3.2 billion people are globally at risk of being infected with 
Plasmodium, the causative agent of malaria1. In 2015, 212 million cases and 
429,000 deaths occurred globally, with 92% of these malaria deaths occurring in 
sub-Saharan Africa2 
 
The nature of malaria morbidity and mortality can be affected by the level of disease 
transmission. In stable transmission areas, fatality rates may reach 2-3%3; while in 
low seasonal transmission settings, where the population fails to sustain disease-
modulating immunity, it is even 10 times higher4. In areas with unstable malaria 
transmission, high risk for severe disease is expected in younger children5 while 
cerebral manifestations is likely to happen in older children and adults6 leading to 
different socioeconomic consequences.    
 
With the expansion of malaria interventions through an improved access to accurate 
diagnosis, introduction of effective antimalarial medicines and scale up of vector 
control coverage, the burden of the disease significantly declined globally between 
2000 and 2015 with a reduction of malaria incidence and mortality by 41% and 62%, 
respectively2. In Africa, the mortality rate has reduced by 66% in the same period1, 
even though the disease is still a major cause of morbidity and mortality on the 
continent (Figure 1).  
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Figure 1. Categorization of countries as malaria-free, eliminating malaria, or 
controlling malaria, 2015 
Source: Newby et al 2016. The Lancet; volume 387, Issue 10029, Pages 1776. 
DOI: 10.1016/S0140-6736(16)00230-0  
Reprinted with permission from the Elsevier. 
 
However, the effect of these interventions on the reduction of malaria transmission in 
much of sub-Saharan Africa have been only modest7. An increasing trend in 
Plasmodium falciparum burden has been recently reported from Mozambique after a 
successful decline in the prevalence, emphasizing the need for sustained malaria 
control with proven interventions8. Additionally, the declining trends of malaria 
prevalence achieved during the past decade are threatened by emerging resistance 
to the pyrethroid group of insecticides9 and by the emergence of artemisinin-resistant 
malaria parasites10. 
 
1.2 Life cycle and causative agents of malaria 
Malaria is caused by a protozoan parasite of the genus Plasmodium that infects 
humans and female Anopheles mosquitoes. There are five species of Plasmodium 
10 
 
that infect humans, namely P. falciparum, P. vivax, P. malariae, P. ovale and P. 
knowlesi (a simian malaria parasite that can be transmitted to humans and causes 
disease11,12). P. falciparum is the most virulent species, responsible for almost all 
mortality due to malaria in Africa. Malaria parasites have complicated and fascinating 
life cycles with the development of the parasite both in humans and in the female 
Anopheles mosquito (Figure 2). When an infected mosquito bites a human for a 
blood meal, the parasites are injected in the form of sporozoites into the skin and 
capillaries with the mosquito's saliva. The sporozoites travel to the liver and multiply 
asexually in the liver cells to produce tens of thousands of merozoites from each liver 
cell within 5-16 days depending on the species. Some Plasmodium species (P. vivax 
and P. ovale) can remain dormant for extended periods in the liver, resulting in 
relapses weeks up to years later13–15. After the exo-erythrocytic schizogony, the 
merozoites leave liver cells and enter the bloodstream and infect red blood cells 
where they initiate asexual multiplication cycles (blood schizogony) that produce 8 to 
24 new infective merozoites when the cell ruptures within 1-3 days depending on the 
species. The newly formed merozoites continue to repeatedly invade more 
erythrocytes and result in millions of parasite-infected cells in the host bloodstream, 
causing fever commonly when parasites egress from erythrocytes and invade new 
red cells. Some individuals control parasitemia and remain afebrile in malaria-
endemic areas and an age-dependent fever threshold effect is apparent16. 
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Figure 2. Plasmodium life cycle. 
Source: https://www.cdc.gov/dpdx/malaria/index.html ("DPDx - Malaria Image 
Library") 
Reprinted with permission from Centers for Disease Control and Prevention (CDC). 
 
Some merozoites leave the cycle of blood-stage asexual multiplication and 
differentiate into sexual erythrocytic stages forming male and female gamete 
precursors called gametocytes. Gametocytes are highly specialized form of the 
parasite responsible for its transmission. The gametocytes are ingested when a 
female Anopheles mosquito bites an infected human and develop into mature cells 
called gametes and complete the sexual cycle in the mosquito that takes 10-18 days 
depending on species and temperature. In the midgut, the male and female gametes 
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fuse and form diploid zygotes that develop into actively moving ookinetes. The 
ookinetes move into the mosquito midgut wall and form oocysts. Inside the oocyst, 
thousands of sporozoites are produced that travel to and invade the mosquito 
salivary glands. When the infected mosquito bites another human, the malaria life 
cycle perpetuates through the inoculation of the sporozoites from its salivary glands. 
The mosquito is acting as a transmission vector, commonly without significant 
impairment by the presence of the parasites17,18. 
 
1.3 Plasmodium falciparum infection and gametocyte carriage 
In the natural P. falciparum infection cycle, a continuous production of gametocytes 
results from untreated asexual infections19. After commitment to gametocytogenesis 
immature forms (stage I-IV) sequester in the body (mainly in bone marrow) for a 
maximum of 12 days until they become mature (stage V)20 gametocytes and appear 
in the circulation (Figure 3). During gametocyte development, stage-specific mRNA 
is transcribed even though no genomic replication is present. Gametocyte carriage 
refers to the presence of sexual forms of the parasite in the body of infected person 
being sequestered in the tissues of internal organs and later circulating in peripheral 
blood till they decay spontaneously, by immune attack or drugs.  
 
 
 
Figure 3. Simplified Plasmodium falciparum life cycle, focusing on 
gametocytogenesis. 
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Source: Lucantoni and Avery 201221, Future Medicinal Chemistry, Vol. 4, No. 18, 
Pages 2338. 
DOI 10.4155/fmc.12.188  
Reprinted with permission from the Future Medicinal Chemistry 
1.3.1 P. falciparum gametocyte commitment and longevity 
Gametocyte commitment and carriage have been associated with the occurrence of 
a variety of conditions unfavorable for asexual growth. The commitment rate 
commonly depends on the type of treatment taken22, density of asexual infection23, 
period of infection24, acquired immunity, presence of anemia24,25, and other 
hematological and parasite genetic factors. After clearance of the asexual infections 
by drug or immune response, gametocytes can still be detected in peripheral blood 
of the infected person for prolonged time till they decay or are killed by the effect of 
immune response or treatment against these transmission stages26. The mean and 
maximum circulation time of mature gametocytes (after period of sequestration and 
being released to the circulation) are estimated in vivo by microscopy as 6.4 and 22 
days, respectively20. This was further confirmed by PCR with a mean circulation time 
of 4.6-6.5 days26. The latter reported a much longer gametocyte carriage 
(sequestration plus circulation time) of low density gametocytes, as 13.4 and 55 days 
after ACT and non-ACT treatment, respectively26. These few gametocytes that 
remain in the blood for an extended period might be enough to be transmitted to 
mosquito as the transmission can occur even at a submicroscopic level27. A 
prolonged presence of mature gametocytes (their lifespan) in the blood has great 
epidemiologic importance as it increases the chances of infectivity and transmission 
to mosquito. However, except a handful of reports that rely on the estimation of the 
in vivo longevity (mostly using modelling), the gametocyte lifespan was not studied 
experimentally in vitro. Here in this thesis, additional data is presented that shows 
the in vitro lifespan of gametocytes. 
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1.4 Immune response to malaria and development of transmission 
blocking vaccine 
Natural infection with malaria parasites leads to an immune response that is 
regulated by the innate (natural) and adaptive (acquired) immune system which is 
further classified into humoral and cell mediated. The interaction of malaria parasite 
proteins with the immune system of the host plays a role in the pathogenesis of the 
disease.  
 
1.4.1 Innate immunity 
Innate immunity is a fast-acting inherent refractoriness of the host against the 
parasite (sporozoites). It is not dependent on previous antigen encounter, but 
naturally present in the host and carried out mainly by the complement system 
(humoral) and effector immune cells (cell mediated). The humoral and cellular 
mechanisms of this ‘nonspecific’ defense are poorly defined, despite an emerging 
body of evidence emphasizing the importance of innate immune signaling in the 
activation of adaptive immune responses28.  
 
During the first encounter with the malaria parasite at the inoculation site, a generic 
immune response is initiated that induces the recruitment of immune cells 
(polymorphonuclear neutrophils, resident myeloid cells and inflammatory monocytes 
reviewed in29). During migration from the skin to the liver, sporozoites trigger 
signaling cascade in murine hepatocytes in vitro30. In the liver, the replication of 
sporozoites induces type I and II IFNs-dependent functional innate immune 
responses31,32 in mice. The type I IFN signaling is needed for the recruitment of 
natural killer T cells that plays a role in reducing liver infection during secondary 
sporozoite infection32, though it does not have impact on the growth of exoerythroctic 
forms released from the hepatocytes after the primary infection31,32.  
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In humans the significance of innate immune response is not clear. Generally, the 
response to sporozoite inoculation is not measurable, presumably due to the low 
number of inoculated parasites, whereas systemic inflammatory response to asexual 
blood stage infection is strong and can lead to sepsis-like syndromes. Captured 
parasite antigens, after being ingested and processed by antigen presenting cells 
(mainly dendritic cells), are presented to T cells as antigen-MHC complexes. This 
leads to the expression of pro-inflammatory cytokines, and co-stimulatory molecules 
for subsequent initiation of the antigen-specific adaptive immunity mediated by B and 
T lymphocytes33. Several studies have shown that after activation by antigen 
presenting cells (APCs), CD4+ T cells initiate antibody-independent non-specific 
parasite killing by producing pro-inflammatory cytokines and stimulate macrophages 
to kill parasites intracellularly or via oxygen and nitric oxide radicals34. However, the 
CD4 cytotoxic effect is controversially discussed and the B-cell independent parasite 
killing is not achieved in some situations35,36.  
 
The mechanism of antigen capture and presentation for primary activation of CD8+ T 
cell is not well known. However, it is assumed that sporozoite antigens are shed in 
the cytosol of various cell types during cell traversal during the migration of 
sporozoites from the skin to liver and these antigens are processed and presented 
by dendritic cells (reviewed in29). Additionally, antigens expressed in hepatocytes 
during the development of exoerythrocytic forms are shown to prime protective CD8+ 
T cells37, followed by the differentiation of these cells into liver-resident memory 
CD8+ T cells, a key determinant of protective immunity against pre-erythrocytic 
stages38.   
 
1.4.2 The adaptive (acquired) immunity to malaria 
Following the initial defense by the innate immune responses, naturally acquired 
adaptive mechanisms mediated by B and T lymphocytes are required for control of 
parasite-mediated pathology. Acquired immunity is provoked by the malaria parasite 
antigens which changes throughout the complex parasite life cycle. Acquired 
immunity is species-, stage-39, and strain-specific40. Immune protection is usually 
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non-sterile and short-lived, requiring lifelong repeated parasite exposure and 
episodes of clinical disease41. Adaptive immunity recognizes pathogens by 
rearranged high affinity receptors and often involves cell proliferation, gene activation 
and protein synthesis. It is hence not rapid enough to act early in infection unlike the 
innate immune defense. Acquired immunity against Plasmodia have been defined as 
either anti-disease, anti-parasite, or sterilizing immunity41,42. Fully protective anti-
parasite immunity can develop in areas with stable malaria transmission following 
frequent and multiple infection resulting in very low or undetectable parasitemia and 
an asymptomatic carrier status. Only partial immunity is acquired in people living in 
unstable endemic areas. Complete sterile immunity is usually not achieved naturally, 
except when administered experimentally as reported earlier in sporozoite-induced 
liver-stage immunity43.  
 
Although the pre-erythrocytic stage and gametocytes are also targeted, acquired 
immunity is directed predominantly against the asexual erythrocytic stages in 
circulation, mainly the extracellular merozoites, with little effect against developing or 
mature trophozoites42. Acquired immunity to malaria has two arms: antibody-
mediated and cell-mediated immunity. Antibodies are particularly important for 
asexual and sexual blood stage immunity, whereas cell-mediated immune 
mechanisms are essential to suppress liver stage development.  
 
1.4.3 Humoral (antibody-mediated) immunity  
In areas with stable and intense malaria transmission children born to immune 
mothers are protected from malaria in the first months of life by means of passive 
immunity (by maternal antibodies) followed by few years of susceptibility before the 
acquisition of active immunity44. Antibodies are important mediators of immunity to 
malaria and their protective role has been shown earlier45,46: e.g. parasitemia and 
clinical disease were reduced in Thai P. falciparum-infected patients after passive 
transfer of IgG from immune donors46. A central role of humoral immunity has been 
additionally demonstrated in rodents: Mice lacking B cells were unable to clear 
blood-stage parasite infection35. 
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Antibody production is induced during malaria infection with IgM and IgG being the 
predominant type. Antibodies protect against malaria by a variety of mechanisms 
including blocking the invasion of sporozoites into liver cells, inhibition of merozoite 
invasion of erythrocytes47, prevention of intra-erythrocytic growth and release from 
schizonts48. Antibodies also prevent binding and sequestration of infected 
erythrocytes in small vessels to enhance their clearance from the circulation by the 
spleen49,50. They also disrupt resetting or spontaneous binding of uninfected RBCs to 
RBCs infected with late-stage asexual parasites51. Additionally, in collaboration with 
other immune cells, Plasmodia antigen-specific antibodies play a role in parasite 
clearance by opsonization of infected erythrocytes to increase their susceptibility to 
phagocytosis and cytotoxicity by various immune effector cells52.  
  
1.4.4 Cell-mediated immunity 
Cell-mediated immunity in malaria may protect against both pre-erythrocytic and 
erythrocytic parasite stages. CD8 T cells have important effector functions in pre-
erythrocytic immunity53, however there is little evidence of their role against blood 
stage infection, possibly because CD8 T cells provide protection by lysing infected 
cells through major histocompatibility complex (MHC) antigen expression which is 
not present in erythrocytes54. In pre-erythrocytic stage, CD8 T cells attack parasite-
infected liver cells by secreting lysis factors, like perforin and granzyme B55. 
 
In contrast, CD4 T cells are essential for immune protection against pre-erythrocytic 
and asexual blood stages via cytokine production and modification of B cell56 and 
CD8+ T cell responses57. They play a major role in the acquisition and maintenance 
of protective immune responses to malaria infection58. It has been shown in vitro that 
CD4 T cells from malaria exposed people respond to P. falciparum blood stage 
antigens by proliferation and then production of IFN-γ and/or IL-456. CD4+ T cells 
regulate humoral immune response by activating B cells to differentiate and produce 
P. falciparum-specific antibodies59. Some CD4 T cells (Tregs) play role in regulating 
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the pro-inflammatory immune response that may lead to severe illness and 
mortality60,61. 
 
1.4.5 Antibody response to P. falciparum gametocytes  
Antibodies are the main mediators of sexual-stage immunity to malaria62. The 
presence of sexual-stage specific immune response to malaria is evidenced in 
several studies showing their partial transmission reducing effect. This immunity 
targets the formation and maturation of gametocytes in the circulation and also the 
fertilization and further sporogonic development in mosquito. A humoral immunity 
targeting epitopes expressed on the surface of gametocytes and/or gametocyte-
infected erythrocytes plays a major role in limiting the transmission of the parasite, 
while the CD8+ T cells are not the main part of transmission reducing immunity as 
erythrocytes do not express major histocompatibility complex (MHC) molecules and 
lack processing organelle for the complex of MHC-I and antigen, as reviewed by 
Stone et al63. 
 
During natural infection, following exposure to the sexual stage parasites, individuals 
from malaria endemic areas develop transmission reducing antibody responses64 
against proteins expressed on the surface of gametocytes65. These sexual-stage 
specific antibodies are commonly detected during P. falciparum infection and their 
transmission blocking effect are shown by standard membrane feeding assays66–68. 
Sexual stage-specific antibodies affect gametocyte maturation69 and density70,71 in 
infected individuals. More importantly, these antibodies are taken up by mosquito 
during blood meal together with other components of the immune system, including 
cytokines and complement, and during the sporogonic phase of the Plasmodium life 
cycle, these molecules mediate the lysis of gametocytes, prevent fertilization and 
interfere with further parasite development in the mosquito67,72,73. 
 
Antibody response to gametocyte-infected erythrocyte surface antigens are not well 
investigated compared to the commonly evaluated gametocyte surface proteins, 
19 
 
pfs230 and pfs48/45. A strategy that aims to identify gametocyte-specific epitopes on 
the surface of infected erythrocyte might be a new approach in finding a novel 
gametocyte vaccine target. It was shown in a Thai cohort that naturally acquired 
antibodies bound to gametocyte-infected erythrocytes, distort the morphology and 
maturation of immature gametocytes and limit parasite transmission to mosquitos69. 
Sexual-stage antibody immunity was also observed in sera of Gambian children 
against surface antigens of mature gametocyte-infected erythrocytes that increased 
with age and associated with decreased gametocyte density, indicating that humoral 
immunity may interfere with gametocyte production and viability71. In line with this, in 
this PhD work, the natural immune response to mature gametocyte-infected 
erythrocytes was assessed in clinical samples to confirm previous findings and 
evaluate the influence of vaccination and co-infection on antibody response towards 
gametocytes. 
 
1.4.6 Transmission blocking candidate vaccines 
Several malaria candidate vaccines targeting the different stages of the parasite are 
under development as new and cost effective interventions for the control of 
malaria74. In particular with the aim to inhibit parasite development within the 
mosquito and interrupt the transmission of the parasite to the vector, transmission 
blocking vaccines (TBVs) that target surface protein on the sexual/sporogonic stages 
of the parasite or mosquito midgut antigens are in development75 though at a much 
earlier stage, with the leading candidate of the TBVs (Pfs25) at phase I clinical trial76.  
 
Even though the potential of this approach has been appreciated, the development 
and licensure pathways for TBVs are not well defined. A number of P. falciparum 
antigens have been developed in pre-clinical studies as transmission blocking 
vaccine candidates. The ability of leading TBV candidate antigens Pfs230, Pfs25 and 
Pfs48/45 to induce a transmission-blocking response has been examined in different 
laboratories. Transmission blocking antibodies targeting sexual-stage specific 
antigens were evaluated in several clinical samples using a standard membrane 
feeding (functional) assays. Antibodies to the above-mentioned antigens have shown 
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in vitro transmission blocking effect in mosquito feeding experiments supporting their 
candidacy as transmission blocking vaccine. However, efficacy of such a vaccine 
can only be measured on population level. Therefore they are often combined as 
part of multistage vaccines. 
 
Among the different lead candidate TBVs that target parasite surface antigens 
expressed either in the pre-fertilization stages within the human (for example 
Pfs48/4577 and Pfs23078) or post-fertilization stage within the mosquito (for example 
Pfs2577 and Pfs2879), only Pfs25 has been tested in phase I human clinical trials and 
induced transmission blocking antibodies even though the study was terminated due 
to the associated systemic adverse events76, possibly related to the specific 
antigen/adjuvant combination used in the preparation. Adjuvant related limitations 
and immunogenicity of Pfs25 TBVs has been improved by using purified Pfs25 
protein expressed in E. coli80 and other organisms and through conjugation of the 
antigen to carrier proteins with known high immunogenicity81. Currently, Pfs25 
antigen chemically conjugated to E. coli-expressed ExoProtein A (EPA) is advancing 
to a phase 1 human trial in endemic settings (reviewed in82).  
 
The post-fertilization proteins, Pfs25 and Pfs28, are not expressed in the vertebrate 
host, and hence not exposed to the host immune selection pressure and appear to 
have limited antigenic variations83,84, which qualify them to be broad-acting vaccine 
candidates. A very different transmission blocking approach targets the mosquito 
midgut ligands required for ookinete interaction. Antibodies elicited against mosquito 
midgut proteins (such as A. gambiae midgut glycoprotein, Anopheline Alanyl 
aminopeptidaseN [AnAPN1]) have demonstrated transmission blocking activities85.  
 
Despite very slow progress in the last decades, there is currently a promising 
improvement in the development of transmission blocking and other malaria 
vaccines. However, still more work has to be done to explore different targets of 
parasite or mosquito stage proteins so as to fill the gap in finding a good 
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transmission blocking vaccine. As sexual stage antigens are under less immune 
selection pressure, they are likely to have minimal antigenic variation compared to 
vaccine antigens to other stages of the malaria lifecycle. The development and 
inclusion of TBVs as malaria control strategy would therefore make a significant 
change in malaria epidemiology. TBVs could prevent the spread of the disease in the 
community including in countries with high malaria transmission. The vaccine could 
help to accelerate elimination of the disease from areas with low and seasonal 
malaria transmission and eventual eradication.   
 
1.5 Treatment and control of malaria 
Malaria is a curable disease if promptly diagnosed and treated. Treatment should be 
initiated as soon as possible as the disease can be deadly if there is a delay in 
diagnosis especially when caused by P. falciparum. The primary aim of malaria 
treatment is a rapid and complete elimination of the parasite. Antimalarial drugs or 
combinations with an additional transmission blocking effect would be particularly 
beneficial on the population level, because they would reduce spread of parasites; in 
particular, strains that developed resistance.  
 
A good antimalarial treatment for uncomplicated cases needs to be available as oral 
formulation, administered with limited number of doses (preferably only one), with 
very good therapeutic effect and safety profile, with long term protection and delay 
for emergence of resistance, whereas treatment for severe cases needs a parenteral 
formulation with fast-acting drugs that are fully active against all strains. In the past, 
P. falciparum has shown a widespread resistance to various antimalarial 
chemotherapies. There are several antimalarial drugs that are administered 
depending on the species of Plasmodium and the sensitivity of the parasite species. 
Artemisinin-based combination therapies (ACTs) are the most effective antimalarial 
drugs available today for uncomplicated P. falciparum malaria86. Five different ACTs 
have been recommended by the World Health Organization (WHO)87 and among 
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these combinations artemether-lumefantrine (AL) has been the most widely 
prescribed ACT in sub-Saharan Africa.   
 
Different malaria control strategies work together to interrupt the transmission of 
parasites (vector control), the establishment of blood-stage infection in humans 
(chemoprevention) and the development of illness and severe disease (management 
of cases)1. It is estimated that the reduction of malaria cases in sub-Saharan Africa 
between the year 2000 and 2015 was achieved mainly (70%) by malaria control 
interventions. Among the averted cases, 79% were estimated to be averted through 
the use of vector control measures and 21% by artemisinin based combination 
therapy1.  
  
However, the emergence of parasite resistance to the currently used combination 
drugs (ACT) in five countries of the so called ‘Greater Mekong sub region (GMS)’ 
and resistance of mosquitoes to various insecticides in almost all African countries 
are challenges of malaria control strategies that may reverse the declining trend of 
malaria incidence if unaddressed. A recent report has shown the development of P. 
falciparum resistance to both fast-acting (artemisinin derivative) and long-acting 
(partner) combination drugs in a multisite prospective study in Cambodia10. The 
distribution of insecticide treated mosquito nets is still inadequate in malaria 
transmission areas of sub-Saharan Africa. The coverage of indoor residual spraying 
is decreased these days and mosquito resistance to at least one insecticide occurred 
in 60 countries since 20101. Despite the improved intervention, millions of people still 
lack access to accurate diagnosis and treatment. The progress towards the 
improvement of preventive therapies for pregnant women and adoption of preventive 
therapies for children under five is slow.   
 
1.5.1 Effect of antimalarial drugs on P. falciparum gametocytes 
Gametocidal activity of antimalarials is highly desirable for malaria control and 
prevention of spread of resistant parasites and for the final elimination and 
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eradication agenda88. Although most currently used antimalarial drugs, though they 
are active against the asexual blood-stage parasites89–91, they have no effect against 
mature P. falciparum gametocytes92, aside from a modest effect on the early stages 
of the sexual forms of the parasite. Some antimalarials may even increase the 
gametocyte carriage rate and transmission of malaria93, which would be devastating 
if it results in the selection of drug resistant parasites. A recent report has shown that 
patients carrying artemisinin resistant parasites more often develop gametocytemia 
before or after treatment with artemisinin combination therapies than those having 
artemisinin sensitive parasites indicating an increased transmission potential of 
artemisinin resistant parasites94. This remains a big challenge for the control of 
malaria and resistance containment unless effective and safe gametocidal drugs are 
accompanied with the drugs targeting the asexual stages. 
 
Based on the effect on the asexual95 and early gametocyte stages96 artemisinin 
combination therapies have been shown to have an important public health benefit in 
reducing gametocyte carriage97 and thereby reducing patient infectivity and malaria 
transmission98. However, ACTs are not active against the matured sexual forms 
responsible for the transmission of the parasite from human to the vector. 
 
Even though primaquine, an 8-aminoquinoline, has shown proven gametocytocidal 
activity against matured gametocytes in vivo99,100, its use is limited due to its serious 
safety problems (risk of hemolysis) in glucose-6-phosphate dehydrogenase (G6PD)-
deﬁcient individuals. 8-aminoquinoline drugs are also reported to have low efﬁcacy in 
poor metabolizers of CYP2D6 in humans101,102. The same safety and efficacy issue 
is the concern of other related 8-aminoquinolines; bulaquine with a potential 
gametocidal activity103 and tafenoquine104, which is at the late-phase of clinical 
development. A single low dose of 0.25 mg/kg primaquine as a P. falciparum 
gametocytocide was recently recommended by World Health Organization (WHO) 
replacing the previously recommended dose of 0.75 mg/kg for a use together with 
artimisinin combination therapy105. As reviewed by Uthman et. al.106, some studies 
tested low-dose primaquine (single-dose of 0.1 to 0.25 mg/kg) in G6PD-deficient 
individuals and have reported less marked falls in average haemoglobin compared to 
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the higher dose (0.75 mg/kg). In line with this, a recent meta-analysis study reviewed 
that primaquine was not significantly different from other drugs in the incidence rate 
ratios for adverse effects107. However, another recent study showed that even the 
lower (0.25 mg/kg) single-dose of primaquine resulted in greater fall  in haemoglobin 
concentration in G6PD-deficient patients who received primaquine than in those who 
did not108. Currently, there is no alternative safe and effective gametocidal drug 
licensed for the control of P. falciparum transmission.  
 
1.5.2 Novel compounds with gametocidal activities 
Chemotherapy plays a great role in the treatment and control of malaria, however, 
emergence of drug-resistance is a major threat of chemotherapies. The parasite has 
developed resistance in the past to several registered antimalarials109, including 
growing reports recently of delayed response to artemisinin derivatives in Southeast 
Asia110. Therefore, new drugs need to be developed to back up the currently 
available drugs before they fully lose their activity. Much work has to be done 
especially in exploring novel compounds against the sexual stages of P. falciparum 
where currently there is no effective and safe drugs proven for public use. Such 
drugs would be central to fight malaria and the spread of resistance on the 
population level and shall be included in the pipeline for discovery and development. 
In this PhD work, the gametocidal effects of several fluorescent dyes and a 
macrolide compound chlorotonil A are evaluated.  
 
1.5.2.1 Gametocidal activities of fluorescent dyes 
Since the late 19th century, several synthetic dyes have been tested for their 
antimalarial activity111,112, starting with the pioneering work of Guttmann and Ehrlich 
who discovered the antimalarial activity of the thiazine dye methylene blue113. 
Methylene blue has been shown to have strong gametocytocidal effect and potent 
transmission-blocking activity in vivo114,115 and in vitro116,117. 
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A recent in vitro study identified several synthetic dyes with high levels of antimalarial 
activity against the asexual blood stages of P. falciparum parasites118. To further 
explore the activity of fluorescent dyes against the sexual stages of P. falciparum 
responsible for the transmission of malaria, the effect of a panel of fluorescent dyes 
against gametocytes was assessed in this PhD work using an ATP-based 
bioluminescence assay. In this work, fluorescent dyes were found with high levels of 
inhibitory activity against mature P. falciparum gametocytes of the 3D7 laboratory 
strain and clinical isolates from Gabon119.   
 
1.5.2.2 Gametocidal activities of chlorotonil A 
Plants, fungi and bacteria are a rich source of biologically active natural compounds 
and their derivatives to develop effective chemotherapeutics against infectious 
diseases including malaria. Among these, the soil-dwelling myxobacteria are known 
producers of novel biologically active natural products120–122. In primary screening of 
a library of secondary substances from myxobacteria, particularly Sorangium 
cellulosum strains, at the Swiss Tropical and Public Health Institute, the 
antiplasmodial activity of a chlorine-containing metabolite, chlorotonil A was 
identified. Gerth et. al. have first isolated and described the structure of chlorotonil 
A123 and Rahn and Kalesse later reported the total synthesis and the dehalogenated 
form of the substance124. The compound is complex and poorly soluble in water and 
organic solvents123. In this PhD work, the gametocidal activity of chlorotonil A was 
investigated in vitro against late-stage P. falciparum gametocytes with an established 
bioluminescence assay. Here it is shown that chlorotonil A had an inhibitory effect at 
concentrations well below any of the available antimalarials.    
 
2 Aim of the PhD work 
The institute and the study group where there PhD project was completed is involved 
in several studies on the investigation of malaria transmission, immunity and drugs 
targeting the P. falciparum, the most important causative agent of malaria. There is 
little information about the biology of the transmissible stage of the parasite and no 
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safe and effective drug and vaccine is on the market to block the transmission of the 
parasite from human to mosquito.  
 
In order to contribute to the knowledge of P. falciparum gametocyte biology, a 
gametocyte in vitro culture was established and several experiments were performed 
to assess the development and longevity of mature gametocytes, to explore 
acquisition of anti-gametocyte immunity and evaluate susceptibility of mature 
gametocytes to drugs. The assessment of gametocyte lifespan is done here 
experimentally for the first time in vitro to confirm the previous in vivo modelling 
estimate of gametocyte longevity. The survival of in vitro differentiated gametocytes 
was evaluated by microscopy, flow cytometry, and real time quantitative polymerase 
chain reaction (RTqPCR). Moreover, natural antibody response to the surface and 
intracellular antigens of mature gametocyte-infected erythrocytes was explored using 
previously collected samples from two separate studies (two phase I clinical trials of 
GMZ2, a malaria candidate vaccine) from Gabon. For this purpose, a flow cytometry 
based immunoassay was used to quantify anti-gametocyte IgG antibody response to 
P. falciparum sexual stage antigens. Additionally, new compounds (several 
fluorescent dyes and chlorotonil A) were tested for their activity against the 
transmission stages of P. falciparum clinical isolates and laboratory strains. To 
achieve this aim, an ATP based bioluminescence assay was used to measure the 
viability of the parasites.  
 
The specific objectives of this PhD work are presented as follows. 
1. To investigate the life span of in vitro cultivated P. falciparum gametocytes. 
2. To explore natural antibody response to P. falciparum gametocyte-infected 
erythrocytes and evaluate the effect of vaccination with GMZ2 (candidate 
malaria vaccine) and intestinal parasite infection on the development of 
antibody response to gametocytes. 
3. To evaluate the activity of fluorescent dyes against mature (stage V) 
gametocytes of the laboratory strain 3D7 and clinical isolates in comparison to 
previously described antimalarials. 
4. To assess activity of chlorotonil A against mature sexual stages of the P. 
falciparum 3D7 laboratory strain.  
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3 Results 
The summary of the results from different studies making up this PhD work is 
presented here. Figures and tables from each of the papers are referred to in the 
text. 
 
3.1 Manuscript I (published) 
Life-span of in vitro differentiated P. falciparum gametocytes 
Tamirat Gebru, Albert Lalremruata, Peter Kremsner, Benjamin Mordmüller, Jana 
Held 
Malar Journal. 2017;16 (1): 330 
The sexual stages of Plasmodium parasite (gametocytes) are responsible for the 
transmission of the parasite from humans to mosquitoes. It has been reported that 
mature gametocytes stay in infected individuals for several weeks being infective to 
the mosquito for a number of days. Previous assessments were made in vivo by 
microscopy20,125 and PCR126 following clearance of the asexual stages, and the 
longevity was estimated by mathematical modelling20,126 assuming a constant 
sequestration period and an exponential decrease of circulating gametocytes with 
their age. To confirm the previously reported modelling estimate and present a better 
representation of the natural survival time, the gametocyte lifespan was assessed 
here using three viability methods (microscopy, flow cytometry, and RT-qPCR) for 
the first time in vitro. Gametocytes of one clinical isolate and one laboratory strain 
were followed in culture until they decayed naturally.   
 
The gametocytes appeared healthy for several days by microscopy (Figure 1 - 
Manuscript I) and were detected for 39-46 days after initiation of the gametocyte 
culture, with a half-life of 2.6 days on average. The highest gametocytemia was 
observed between 20 to 22 days (Figure 2 – Manuscript I). In vitro longevity after 
reaching maturity reflects the in vivo circulation time of the mature forms. Assuming 
gametocyte maturation at the peak of gametocytemia (as some gametocytes did not 
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mature before peak), the mature gametocyte longevity was calculated by subtracting 
the number of days needed to reach peak gametocytemia from the recorded 
longevity. Therefore, mature gametocyte longevity, mean 50% and 10% survival rate 
were 18-26 days, 2.6 days, and 10 days, respectively (Table 1 – Manuscript I). NF54 
had longer longevity than the tested clinical isolate (JH013). The ex-flagellation 
assay also demonstrated that mature male gametocytes can ex-flagellate for two 
weeks (Figure 2 – Manuscript I). 
 
Gametocyte longevity was also evaluated by flow cytometry using a previously 
published assay of hydroethidine staining. Hydroethidine needs to be metabolized by 
live parasites to be converted to ethidium which can emit a red fluorescence when 
excited after interaction with the parasite nucleic acids. Gametocytes were detected 
by flow cytometry for 45 – 49 days after initiation of culture (Figure 3 – Manuscript I) 
and peak gametocytemia was recorded on day 16. Considering the day of peak 
gametocytemia as the day of maturation, mature gametocytes had longevity of 16-24 
days. Mature gametocytes had on average 50% and 10% survival rate of 6.5 and 12 
days, respectively (Table 1 – Manuscript I). Gametocyte longevity was higher in 
NF54 laboratory strain, followed by P. falciparum clinical isolate (JH013, collected 
from plasmodium infected people in Gabon) and 3D7 laboratory strain.  
 
When assessed by molecular technique using RNA based quantitative real-time 
polymerase chain reaction (RTqPCR), the gametocytes were detected for longer 
than 50 days of the gametocyte culture. Two previously published, PF14_0367 
(middle and late stage) and Pfs25 (late stage), gametocyte markers were used 
(Figure 4 – Manuscript I). Peak gametocytemia was recorded on 18 and 20 days 
after initiation of culture for NF54 and JH013, respectively. NF54 had longer lifespan 
than the clinical isolate (JH013). Estimated gametocyte circulation time (mature 
gametocyte longevity) was 31 and 26-32 days for NF54 and JH013, respectively. 
The mean 50% and 10% survival rate was 3.5 days and 12 days, respectively (Table 
1 – Manuscript I). 
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Additionally, rate of gametocytogenesis was assessed in vitro in different strains of 
P. falciparum in the presence or absence of serum supplementation. Highest 
gametocytemia was observed in NF54 followed by JH013 and 3D7 (Figure 5 – 
Manuscript I) and serum supplementation enhanced the gametocyte yield. There 
was no statistically significant difference among the strains and between the serum 
supplemented and non-supplemented cultures. All the strains had similar patterns of 
parasitemia.  
 
Overall, the longest gametocyte life span was measured by RTqPCR followed by 
flow cytometry and microscopy. The NF54 strain survived longer than the clinical 
isolates in all the three viability assays and has also shown the highest gametocyte 
yield. This finding is consistent with infectivity and cycle propagation capability of 
strains used in controlled human malaria infection. 
 
3.2 Manuscript II (published) 
Recognition of Plasmodium falciparum mature gametocyte-infected 
erythrocytes by antibodies of semi-immune adults and malaria exposed 
children from Gabon 
 
Tamirat Gebru, Anthony Ajua, Michael Theisen, Meral Esen, Ulysse Ateba Ngoa, 
Saadou Issifou, Ayola A. Adegnika, Peter G. Kremsner, Benjamin Mordmüller, Jana 
Held 
Malar Journal. 2017; 16 (1): 176 
 
With the aim of assessing the natural immune response to gametocytes and 
evaluating the effect of the candidate malaria vaccine (GMZ2) and intestinal 
helminths on the development of natural antibody (Ab) response to gametocytes, Ab 
recognition of P. falciparum mature gametocyte-infected erythrocytes was evaluated 
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in vitro by microscopy- and flow cytometry-based immunofluorescence assay in 
samples collected from 30 children and 32 adults from two GMZ2 trials in Gabon 
(Table 1-Manuscript II). In vitro antigen recognition by Abs considerably increased 
after fixation and permeabilization of P. falciparum gametocyte infected erythrocytes 
(Figure 1-Manuscript II). However, to measure the gametocyte-specific response, 
non-permeabilized cells were used (Figure 2A-manuscript II) for all subsequent 
measurements with the intention to capture erythrocyte surface-expressed antigens. 
The antibody recognition of permeabilized erythrocytes (Figure 2b-Manuscript II) will 
not be fully gametocyte-specific as the detected internal antigens could be shared by 
the asexual stages. 
 
The level of Ab recognition of NF54 laboratory strain showed was similar to the 
clinical isolate (JH013) that was additionally tested. Therefore, the NF54 strain which 
is currently being used in clinical trials was chosen to evaluate the level of anti-
gametocyte Ab response in adults and children. Adults showed higher level of Ab 
response to mature gametocytes compared to children (Figure 3-Manuscript II) with 
the sero-prevalence also being higher in adults (77%) than in children (57%). 
 
Antibody response to gametocytes may be modulated due to GMZ2 vaccination. 
This immune modulation may occur through the diversion of the immune response 
towards the vaccine or by reducing gametocyte density (via limiting the blood stage 
asexual infection) despite the low efficacy of the vaccine in younger children 
between one and five years127. To investigate this, the effect of GMZ2 vaccination on 
the development of anti-gametocyte immune response was assessed in adults and 
children. In adults, significantly lower levels of Abs were observed in GMZ2 
vaccinated individuals on Day 84 (Figure 4A-Manuscript II) compared to baseline 
(Day 0). This difference was not seen in rabies vaccinated adult control group or in 
children vaccinated with either GMZ2 or rabies vaccine (Figure 4B-Manuscript II).  
 
Even though some overlap is expected between antigens expressed at the sexual 
and asexual stages, sexual stage immunity may be developed independently from 
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the asexual-stage immunity. Therefore, possible associations were tested between 
the level of anti-gametocyte Abs and the previously published data of Abs to asexual 
blood stages antigens or GMZ2 vaccine antigen. A positive correlation was shown 
between Ab response to the sexual and asexual antigens in the semi-immune adult 
population but not in children (Table 2-Manuscript II). No association was observed 
between sexual Ab response and Ab to GMZ2 antigen in adults and children.  
 
Prompted by earlier reports on the effect of intestinal helminths on anti-GMZ2 Ab 
responses, the effect of intestinal helminths infection on the anti-gametocyte immune 
response was evaluated in children using the previously published data of intestinal 
parasite burden of all 30 children included in the GMZ2 phase Ib trial. Trichuris 
trichiura and Ascaris lumbricoides were the dominant parasites followed by others 
with very low (< 7%) prevalence including Strongyloides, Schistosoma, and 
Ancylostoma. It was observed that children infected with Ascaris had significantly 
higher anti-gametocyte Ab response compared to uninfected children (Figure 5A-
Manuscript II). When gametocyte-infected erythrocytes were permeabilized and used 
in the assay (which is not sexual stage specific), it was found that naturally acquired 
Ab response was significantly lower in children infected with T. trichiura compared to 
uninfected children (Figure 5B-Manuscript II).  
 
3.3 Manuscript III (published) 
Effect of fluorescent dyes on in vitro-differentiated, late-Stage Plasmodium 
falciparum gametocytes 
Tamirat Gebru, Benjamin Mordmüller, Jana Held 
Antimicrobial Agents and Chemotherapy. 2014; 58 (12): 7398-7404 
 
Drugs that target the transmission of the parasite from an infected human host to 
mosquito vector are highly demanded to block the transmission as currently there is 
no safe and proven anti-gametocyte drug approved for use. Primaquine acts on 
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gametocytes and is licensed but cannot be safely used in G6PD-deficient individuals, 
who represent a significant population of most malaria-endemic areas. In this study, 
based on a previous report on the activity of fluorescent dyes against the asexual 
blood stages of P. falciparum, several potential synthetic compounds were selected 
and investigated for their activity against mature sexual stages using a 
bioluminescence cell viability assay. Viability of gametocytes was assessed by 
microscopy after purification and the gametocytes appeared non-compromised with 
an intact cytoplasm (Figure 1-Manuscript III), male gametocytes showed 
exflagellation, and the mature gametocytes consistently remained viable for an 
average of three weeks. The ATP readout was validated before testing the activity of 
the compounds and showed a close correlation of the ATP level (relative 
luminescence unit) with the number of gametocytes (R2 = 0.99).  
Among the nine fluorescent dyes tested (Figure 2-Manuscript III) five showed IC50s 
below 1 µM (Table 1-Manuscript III) and among these, three mitochondrial dyes, 
MitoRed, DiOC6, and rhodamine B, had IC50s below 200 nM, which is even lower 
than the IC50 of the control dye, methylene blue (770 nM). In particular, MitoRed 
showed high activity against laboratory strain 3D7 as well as against clinical isolates. 
The laboratory strain 3D7 was consistently more sensitive than the clinical isolates 
(2- to 10-fold) for the different dyes as well as the control drugs, particularly 
artesunate and DHA. Activity of primaquine (a prodrug) was low, which is in contrast 
to its strong effect against gametocytes in vivo. This is expected in in vitro assays as 
primaquine is a prodrug that requires activation by cytochrome P450 
2D6 (CYP2D6)128. Epoxomicin, which was used as internal positive control was highly 
active against both; the 3D7 laboratory strain and clinical isolates. With the exception 
of epoxomicin, gametocytes were inhibited at higher drug concentration by all 
compounds compared to asexual blood stages (Table 1-Manuscript III). 
  
Methods used in different gametocyte assays are poorly standardized and different 
approaches are used to assess viability and time of incubation to test gametocidal 
effects of compounds. In this study, the effect of incubation time on the activity of 
compounds was evaluated by incubating fluorescent dyes and standard antimalarial 
drugs with mature gametocytes of 3D7 parasites and clinical isolates for either 24 h 
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or 48 h. The incubation time had no significant effect for most compounds, however, 
MitoRed, the most active fluorescent dye in this assay, was 3-fold more active when 
incubated over 48 h than when used over 24 h (Table 2-Manuscript III). There was 
an even more pronounced (10-fold) increase in the activity of epoxomicin and 
artesunate when parasites were exposed for 48 h.  
 
3.4 Manuscript IV (published) 
 
Antimalarial Activity of the Myxobacterial Macrolide Chlorotonil A 
Jana Held, Tamirat Gebru, Markus Kalesse, Rolf Jansen, Klaus Gerth, Rolf Müller, 
Benjamin Mordmüller 
Antimicrobial Agents and Chemotherapy. 2014; 58 (11): 6378–6384 
 
Similar to the investigation of fluorescent dyes, the activity of Chlorotonil A was 
evaluated in vitro and in vivo against asexual and sexual forms of P. falciparum 
laboratory strains and clinical isolates. Chlorotonil A (Figure 1-manuscript IV) was 
active against 3D7 and Dd2 laboratory strains of P. falciparum (Table 1-Manscript II) 
and did not show a delayed-death effect in a six-day assay with 10.6 nM (3D7) and 
23.5nM (Dd2) IC50s. Chlorotonil A has also shown activity against clinical isolates of 
P. falciparum isolated from patients with uncomplicated malaria in Lambaréné, 
Gabon with a narrow range of IC50s close to those obtained against the laboratory 
strains (Table 2-Manuscript IV).  
 
At least 25 clinical isolates were successfully grown in culture and tested in vitro for 
their sensitivity to chlorotonil A and the control drugs chloroquine and artesunate. 
Chlorotonil A arrested parasite development in different asexual blood stages of the 
parasite. Activity was highest in the ring and trophozoite stages (Figure 2A and 2B-
Manuscript IV), and was still measurable in schizont stages (Figure 2C-Manuscript 
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IV), where artesunate at the same concentration (500nM) could not prevent the 
egress of merozoites from schizonts. Chlorotonil A acts quickly showing activity 
against the ring stage of the parasite, even when incubated only for 1 h with IC50 
close to the one obtained in the standard in vitro susceptibility assay. In vivo, 
chlorotonil A was active against P. berghei in BALB/c mice (97%) administered orally 
at 36 mg/kg, 68 mg/kg, and 110 mg/kg and in Swiss CD1 mice (98%) at 100 mg/kg 
compared to the control mice in a 4-day suppression test with no obvious signs of 
toxicity. However, none of the mice were cleared of their parasitemia completely 
(Figure 3-Manuscript IV) 
Chlorotonil A was evaluated in vitro if it has any effect on the viability of mature 
sexual stages of the laboratory strain 3D7 P. falciparum parasites by an in vitro 
bioluminescence assay. Chlorotonil A was active against stage IV to V gametocytes 
at concentrations close to that obtained against asexual blood stages. However, 
comparator drugs, artesunate and dihydroartemisinin act only when used in very 
high concentrations (Table 3-Manuscript IV). Epoxomicin, the internal control for the 
assay, was highly active against late-stage gametocytes. 
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4 General discussion 
Malaria remains one of the biggest global health threats, even though increased 
funding and implementation of improved tools and strategies of malaria control have 
reduced the global malaria burden since 2000 and revived interest in the elimination 
and eradication of malaria129,130. Development of effective transmission blocking 
drugs and vaccines are considered as an essential components of the Malaria 
Eradication Research Agenda (malERA)88, which complements the primary aim of 
antimalarial treatment that are directed towards removal of the asexual blood-stage 
parasites to cure the illness and prevent or treat severe forms of the disease.  
 
To interrupt malaria transmission, intervention strategies and tools should focus on 
the reduction of the reservoir of infection, the period that a person or a vector is 
infectious, and the speed at which infections are spread. Drugs are essential tools 
for malaria elimination. If they effectively attack all stages of the parasite, they have 
the potential to eliminate last residual foci of infection and interrupt transmission.  
 
Neglected in the past, currently there is an encouraging revival of interest on 
transmission stages of the parasite. However, it is still a long way ahead to 
understand fully the biology, commitment, development, sequestration, longevity, 
infectivity, immune response and drug susceptibility towards P. falciparum 
gametocytes. The four studies presented in this dissertation address the knowledge 
gap in this area. 
 
4.1 In vitro life-span of P. falciparum gametocytes 
Gametocyte maturity, density, sex ratio, and longevity are the main features of 
gametocytes that influence their infectivity to the mosquito. More specifically, the 
circulation time of mature gametocytes in the blood of an infected person will have 
an influence on the transmission of the parasite to the vector. To determine the in 
vivo circulation time of mature gametocytes, the first investigation of this PhD study 
36 
 
explores, for the first time, the period that the sexual stages of P. falciparum can stay 
viable in culture131. It was observed here using three viability assays that 
gametocytes were detected in the range of 39-52 days after initiation of the 
gametocyte culture. This period is assumed to reflect the in vivo sequestration and 
circulation time of the parasite. The average half-life ranged from 2.6 to 6.5 days.  
 
The early forms of gametocytes get sequestered in the body for a maximum of 12 
days20 and appear in the peripheral blood and become infective after further 
maturation in the circulation in 2-3 days125,132. By our protocol, day of maturity was 
not the same for the whole gametocyte population of one culture. We observed that 
all gametocytes got matured on peak gametocytemia after day 12. Assuming peak 
gametocytemia as day of maturation, the mature gametocytes in our assay had 16-
32 days survival time with parasitemia gradually declining. As some gametocytes got 
matured in our culture before the day of the peak gametocytemia, the exact 
gametocyte longevity after maturation (circulation time) could be a bit longer than the 
result we provided. A relatively shorter longevity of mature gametocytes was 
estimated earlier in vivo by microscopy, average 4.6 days (with maximum 24 
days)125 and 6.4 days (with maximum 22.2 days)20. The in vivo evaluation of 
gametocyte longevity might be affected by the host factors (which vary in different 
individuals) and the difficulties of the commonly used mathematical modelling 
method as it is not possible to follow the exact lifespan of parasites in a way similar 
to the in vitro experiment shown here. Other reason for the aforementioned shorter 
longevity period in the in vivo report could be the limit of microscopic identification of 
lower parasitemia of gametocytes in the blood, especially in the later days of follow 
up.  
 
In a previous study, after evaluating gametocytemia by PCR, Bousema et al. 
reported longer gametocyte longevity (55 days) estimating parasitemia using 
mathematical modelling after clearance of asexual parasites126. This is in line with 
the in vitro data presented here observing gametocyte longevity for more than 50 
days when using RTqPCR. For the clinical isolates, the gametocytes were detected 
for 6 more days when Pfs25 is used compared to PF14_0367. This could be due to 
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the relatively higher expression rate of Pfs25 at the sexual stage133. Even though the 
gametocytes persist for longer periods, it is not possible to answer the infectivity of 
old gametocytes from this approach unless a standard membrane feeding assay is 
done. However, it was observed that the mature male gametocytes were able to 
exflagellate for at least two weeks. Earlier, Smalley and Sinden have shown that 
ability of exflagellation by gametocytes persisted for three weeks134.  
 
Additionally, in this investigation, in vitro gametocytogenesis of different P. 
falciparum strains were evaluated. It was found that NF54 parasites are more prone 
to commit into gametocytes than JH013 clinical isolate and 3D7 laboratory strain. 
This confirms an earlier report that showed gametocyte yield depends on the 
parasite line135, as the commitment rely on genetic and environmental factors136. The 
gametocyte production was improved in all P. falciparum parasite strains used when 
serum (from malaria-naïve individuals) was supplemented in the gametocyte culture 
medium. Similar finding was shown earlier with serum from semi-immune 
individuals137. This could be due to an increased production of the asexual parasites 
(a precursor for gametocytes) in the presence of serum from naïve or semi-immune 
people. 
 
Despite their long longevity, the gametocytes in this study have short half-life or 50% 
survival rate (2.5-6.5 days) similar to a previous report (2.4 days)134. The 10% 
survival rate was 10-12 days and there was a steady decline of gametocytemia at 
the later days. Based on previous reports of mosquito infectivity studies, sub-
microscopic gametocytemia could be enough to infect mosquitoes138,139. Therefore, 
the few gametocytes remaining at late time points of incubation in culture might be 
potentially capable of infecting mosquitoes. This should be further investigated with 
membrane feeding experiments. The extended in vitro longevity of gametocytes 
recorded in this study needs to be taken in to account in malaria control programs 
especially for the aim to eliminate the parasite.  
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4.2 Antibody recognition of Plasmodium falciparum mature 
gametocyte-infected erythrocytes  
In the second study, antibody recognition of in vitro differentiated  P. falciparum 
gametocyte-infected erythrocytes140 was explored. Antibody response generated to 
sexual stage P. falciparum parasites has been reported to not only suppress their 
development69, but also influence their survival in the circulation70,71 and also 
interrupt the fertilization of gametes in the vector77. Natural antibody response to 
gametocytes could be initiated towards the parasite internal and membrane bound 
antigens or to the infected erythrocyte membrane proteins. Specific antibody 
response to few gametocyte-specific membrane proteins (mainly Pfs230 and 
Pfs48/45) have been studied earlier and their correlation with transmission blocking 
activities were shown. However, antibody response to gametocyte-infected 
erythrocyte surface antigens is rarely investigated. As this information is vital for the 
design and development of transmission blocking vaccines, here an exploratory 
study was done to investigate the antibody response to P. falciparum mature 
gametocyte-infected erythrocyte surface in vitro in sera from malaria-exposed 
children and semi-immune adults from Gabon. Additionally, the effect of the malaria 
vaccine candidate GMZ2 and worm infection on the development of anti-gametocyte 
antibody response have been evaluated. 
 
In this study, adults had high antibody response compared to children. There are 
contradictory reports on the relation of age with anti-gametocyte antibody response. 
The result here is similar to some of the previous reports141,142 but are not in line with 
others143 that assume antibody response to gametocytes to be not long-lasting. 
Difference between the studies on the age-dependency of anti-gametocyte response 
might be due to different methodologies, varying age-ranges and epidemiological 
settings. Similarly, anti-gametocyte sero-prevalence was higher in adults (77%) than 
children (57%). According to earlier reports, sera from children in Ghana144 and 
Gambia71,141 also have shown similar prevalence of antibody response to the surface 
of gametocyte infected erythrocytes.  
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In addition, the association between antibody response to the asexual antigens 
(whole parasite antigen and GMZ2 [a fusion of MSP3 and GLURP protein]) and the 
development of anti-gametocyte antibody response was evaluated. In adults, there 
was a significant but weak positive correlation between sexual antibody and whole 
asexual antibody response, though not with the GMZ2 antigens. The result shows 
that parasite exposure is associated to antibody response to gametocytes. When the 
effect of GMZ2 vaccination was additionally assessed on the level of antibody 
response, the vaccination led to a reduced sexual antibody response in adults. This 
could be due the influence of the candidate vaccine to divert the immune response 
towards the vaccine or reduce the asexual parasite population leading to a lower 
gametocyte density and sexual antibody response, though the recent report shows 
only 10-14% efficacy of the vaccine in children127. To our knowledge, there is no 
evidence for the expression of GMZ2 component proteins on the surfaces of 
gametocyte-infected erythrocytes that could be the reason why boosting of anti-
gametocyte antibody response was not seen in the vaccinated individuals. In 
children, no correlation was observed between asexual and sexual antibody 
response and the antibody level did not change after vaccination. This might be due 
to the low level of gametocyte-antibody response observed in children that 
decreases the ability to detect differences between the two variables. Additionally, 
the statistical power is limited due to the small sample size. It would be interesting to 
investigate the larger cohort of the recently completed phase II trial. 
 
Previously it was shown that antibody response to the gametocyte-infected 
erythrocytes get enhanced after permeabilization141. Interestingly, the same effect of 
increased antibody recognition with permeabilization and also fixation of the cell was 
seen, as some fixatives might also simultaneously permeabilize the cell145. This 
could be due to the presence of intracellular targets of transmission blocking 
antibodies146. However, the intracellular antigens are largely shared by the asexual 
stages147 and antibody response measured after permeabilization might not be 
gametocyte specific. Therefore, to explore factors associated to the sexual antibody 
response, non-fixed and non-permeabilized gametocyte-infected erythrocytes were 
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used for the analysis of the effect of age, asexual antibody response, GMZ2 
vaccination, parasite strain and worm-infection. 
 
No difference in antibody recognition was detected between the laboratory strain 
(NF54) and a clinical isolate (JH013) from Gabon, though a higher recognition was 
expected from JH013 as it was collected from the area where the study participants 
were recruited from. In agreement to this finding, Dinko et. al. reported earlier that 
plasma antibodies from Ghanian children recognize both 3D7 lab strain and a clinical 
isolate from Kenya with no significant variation in the detection level148. Therefore, 
the antibody response generated towards gametocyte-infected erythrocyte surfaces 
might not be strain specific. 
 
Co-infection with other parasites have been shown to affect antibody response 
towards Plasmodium149 or its candidate vaccine150. In this study, using permeabilized 
and non-permeabilized gametocyte-infected erythrocytes, effect of intestinal helminth 
infection on the anti-gametocyte antibody response was evaluated in children. When 
permeabilized parasites were used, low antibody response towards mature 
gametocytes in Trichuris trichiura infected children was observed. Nevertheless, this 
might not represent suppression of gametocyte specific antibody response by the co-
infected parasite, even though it confirms the previous finding shown earlier for the 
malaria blood-stage asexual candidate vaccine (GMZ2) in the same population 
where the antibody response to the vaccine was 3.4-fold reduced in T. trichiura-
infected subjects150. Similarly, in a cross-sectional study it was shown that another 
helminth (Schistosoma haematobium) infection resulted in reduced gametocyte 
specific (Pfs48/45) antibody titers.  
 
The effect of Trichuris was not seen in the gametocyte-specific assay using non-
permeabilized cells. This might be due to the low level of antibody response to non-
permeabilized gametocyte-infected erythrocytes. This could be due to the presence 
of only small fraction of gametocyte transport proteins that are expressed on the 
surface of infected erythrocytes. To confirm this, the assay was also run using the 
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clinical isolate (JH013) and found similar level of low detection. Surprisingly it was 
observed that Ascaris-infected children had an increased anti-gametocyte immune 
response compared to uninfected subjects. Confirmatory studies with a bigger cohort 
are sought to corporate these findings performed in small sample cohort. Antibody 
response to gametocyte-infected erythrocytes and immune modulatory effects of 
helminths need to be studied further in a big sample size and populations with a 
different level of malaria transmission and co-endemicity. 
     
4.3 Effect of fluorescent dyes on in vitro-differentiated, late-stage 
P. falciparum gametocytes 
In addition to the search for transmission blocking antibodies and vaccines, new 
compounds (drugs) with activity against the transmission stages of P. falciparum are 
needed to sustain malaria control as this aspect is missing in many of the 
antimalarials. In the third investigation of this PhD study, synthetic dyes that are 
normally used for parasite/microbial staining are tested for their activity against late-
stages of P. falciparum gametocytes using ATP-based bioluminescence assay119. In 
this study, the activity of several fluorescent dyes was assessed against this stage. 
Five active dyes were identified with a submicromolar IC50 value against mature 
gametocytes. Three of the dyes (mitochondrial) were more active than the control 
drug (methylene blue) which is known to have a gametocytocidal effect114,115. These 
mitochondrial dyes were not toxic when evaluated against HeLa cells118. Among all 
dyes, MitoRed (that belongs to the rhodamine dyes) was the most active and it was 
also previously recommended for further development based on its high activity 
against asexual stages and least toxicity against HeLa cells118, Further toxicity 
profiles of rhodamine derivatives has been reported in relation to their use for 
cosmetic industry151,152, however, additional safety information on MitoRed is 
missing. Further toxicity studies need to be done for the promising active 
compounds.  
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The enhanced gametocytocidal activity of mitochondrial dyes draws attention to 
consider this target organelle for new antimalarial drug development. Dyes select a 
specific organelle in an organism for targeted inhibitory activity. Similar to 
mitochondrial dyes, the antimalarial drug atovaquone targets the mitochondrion of 
the parasite for its inhibitory activity153, acting as a potent inhibitor of the cytochrome 
bc1 complex of the organelle154. Despite having similar targets to the 
gametocytocidal mitochondrial dyes, atovaquone is not active against the late-stage 
gametocytes89. Therefore, mitochondrial dyes might use a different mechanism of 
action. 
 
In this study, gametocytes from 3D7 lab strain and three clinical isolates from 
Lambaréné, Gabon were evaluated for their sensitivity to the fluorescent dyes and 
control drugs. The clinical isolates were less sensitive compared to 3D7 to all 
fluorescent dyes and comparator drugs except primaquine. This shows the 
importance of drug screening in different strains including clinical isolates collected 
from the field where the drugs will be used. Clinical isolates might be exposed to 
various drugs pressure and it is expected that they might show a different level of 
sensitivity compared to the lab strains. The difference of drug-sensitivity between the 
clinical isolates and the laboratory strain is observed more pronounced in case of the 
artemisinin derivative drugs. One can hypothesize that the exposure is the reason for 
this, but it is not possible to conclude from this study as the drug exposure profile of 
participants was not assessed. 
 
The compounds were more active when tested with a prolonged incubation time (48 
h) than a short exposure (24 h). This could be due to the fact that after application of 
the drugs, the metabolic changes are better detected by the reader after extended 
incubation. A difference in the in vitro anti-gametocyte activity of compounds was 
also observed with a change in the content of culture medium; e.g. artemisinin 
derivatives (artesunate and DHA) showed 10-fold higher sensitivity in this study 
when medium is supplemented with serum119 compared to albumax used in our 
previous assay155. However, artemisinin was not effective156 or had only modest 
effect116,157 in membrane feeding assays, a different and functional way of anti-
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gametocyte drug evaluation. Different assay protocols might result in different 
outcomes. Among the commonly used gametocyte drug-assay protocols, variation is 
commonly observed in number of gametocytes used, incubation period, parasite 
strains, content of culture medium and type of readouts that might lead to up to 
1000-fold difference in the results of the same compound89,157–160.  
 
In general, gametocyte drug assays rely on the evaluation of the viability of the 
parasite. Assays that reflect the parasite biomass are not helpful here since the 
sexual forms are not multiplying unlike the asexual stages. Though new protocols for 
gametocyte production161,162 and drug assay89,116,159,163–166 are being developed, 
better standardization and validation of assay procedures and agreement between 
labs are required to identify compounds with promising activities. 
 
In conclusion, fluorescent dyes, in particular MitoRed, show very high activity against 
mature gametocytes and should be considered for further evaluation to develop a 
new gametocytocidal or transmission blocking drugs. Clinical isolates need to be 
included in the screening of compounds as they can show a different drug sensitivity 
profile. 
 
4.4 Antimalarial activity of chlorotonil A 
In the fourth study155, after exploring susceptibility of asexual parasites, the activity of 
a novel compound, chlorotonil A (produced by a Myxobacterium: Sorangium 
cellulosum) was evaluated against mature gametocytes of P. falciparum. 
Myxobacteria are a valuable source of new chemotherapeutic agents. Among these, 
the genus Sorangium is commonly used to produce new compounds of which some 
are in advanced pre-clinical and clinical development167. S. cellulosum was the main 
producer of chlorotonil A, the compound explored here for its activity against P. 
falciparum. Chlorotonil A has many features that entitles it to be a likely lead 
compound. Multiple antimalarial antibiotics have delayed-effect against P. 
falciparum168, but chlorotonil A is very fast acting, even after short, transient 
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exposure. It is effective against all blood stages of the asexual forms at low 
nanomolar concentrations. As it acts immediately after contact at the early stages of 
the asexual blood stages (ring and trophozoites), it is quite effective in reducing 
parasite biomass and may suppress the release of toxins. Unlike the comparator 
drugs used in this study, chlorotonil A has very rapid onset of action with full activity 
shown in 1 h of contact with the parasite. This rapid onset is quite helpful for quick 
reduction of parasitemia in case of severe malaria and for the immediate action of 
drugs having a short half-life169. The compound is active against chloroquine-
resistant strains and also clinical isolates isolated from individuals living in an area 
with high rates of chloroquine170 and sulfadoxine-pyrimethamine171 resistance.  
 
The mode of action of chlorotonil A is not known, but it is active only in the chlorine 
containing pharmacophore. The dehalogenated form is inactive. Activity of 
chlorotonil A is independent compared to control drugs. This means that it shall have 
a different mechanism of action than the comparator drugs are performing. 
Chlorotonil A was also active in vivo in the murine P. bergei model with low toxicity 
and with possibility for oral administration though it had poor solubility. The solvent 
(tetrahydrofuran) used here to dissolve the substance would be toxic to the mice172, 
and therefore, the compound was administered to the mice as a powder in peanut 
butter.  
 
Chlorotonil A has good activity against the late stage gametocytes, which is usually 
not seen in most commonly used antimalarials. Late-stage gametocytes appear in 
the circulation after a period of sequestration in the tissues of internal organs and 
stay in the blood for an extended period even after treatment with the clinically used 
antimalarials126,173. This stage is not easy to target by drugs. Except the 8-
amioquinolines (which require pre-testing for G6PD deficiency)174, all currently 
available antimalarial drugs including ACT are not effective against the transmission 
stage of P. falciparum, though they are active against the asexual blood stages89–91, 
and have a limited activity against the preerythrocytic stages157,175 and early stages 
of the gametocytes114,176,177. Treatment with ACT has a profound effect in 
gametocyte carriages compared to other non-ACT antimalarials126, possibly due to 
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its effect in reducing asexual biomass and activity against early gametocytes. 
Chlorotonil A was very active against mature gametocytes in the current assay at low 
nanomolar level as measured by an ATP-based bioluminescence assay, whereas 
the activity of artimisinin derivatives to this stage was low as it was also documented 
elsewhere89,92,116,157. A new safe and effective gametocytocidal drug that block the 
infectivity of P. falciparum gametocytes is needed to have an impact on transmission 
of the parasite and for the elimination of the parasite especially in areas with low 
endemicity. In the emergence of antimalarial resistance to the currently used first line 
treatment (artemisinin combination therapy), gametocytocidal drugs would be a 
valuable tool to contain and eliminate resistant parasites.  
 
Based on its unique characteristics of low toxicity, oral availability, rapid onset of 
action, activity against all blood stages including the transmission stages of the 
parasite, chlorotonil A fulfills the criteria to be considered for further assessment from 
a lead compound toward a drug development candidate as antimalarial and 
transmission blocking drug. Recently, improved derivatives of this compound have 
shown enhanced activities against both asexual and mature sexual stages of the 
parasite (unpublished data).  
 
4.5 Conclusions 
After the global decline of malaria prevalence, malaria elimination is on the current 
agenda of malaria control, and now considered as attainable goal for a number of 
malaria-endemic regions, as reviewed by Newby et al178. As the presence of 
gametocytes are responsible for the transmission of the parasite from human host to 
mosquito, these stages of the parasite need to be targeted if elimination or 
eradication of the disease is the final goal. Gametocytes appear in humans within 7-
12 days after initial parasitemia. Human infectious reservoirs, who carry the 
transmissible gametocyte stages are important targets of successful malaria control 
strategies. Transmission blocking drugs and vaccines are considered as important 
tools in limiting the parasite transmission combined with other strategies which are 
already in use in malaria control programs.  
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Despite a key role in the transmission of the parasite from human to mosquito, the 
transmission stages of P. falciparum were neglected in the past and little is known 
about their biology. Here, in this PhD work, lifespan of mature gametocytes, natural 
antibody recognition and susceptibility to novel compounds were investigated using 
established standard procedures. Gametocytes survive in vitro 16-32 days after 
reaching maturity, representing the in vivo transmission period once appearing in 
circulation. Erythrocytes infected with in vitro differentiated laboratory strain and 
clinical isolate were observed to be recognized by serum antibodies from malaria 
exposed children and semi-immune individuals with the antibody response 
influenced by vaccination and co-infecting helminths. Mitochondrial fluorescent dyes 
and chlorotonil A were found to be very active against the mature sexual stages of 
the parasite and are recommended to be considered as lead compounds for further 
development and validation.  
 
5 Personal contributions 
My contribution to the four papers included in this thesis is as follows: 
 
Paper I (published in Malaria Journal): Lifespan of in vitro differentiated Plasmodium 
falciparum gametocytes. 
 Contributed to the study design, 
 Established and performed laboratory experiments, 
 Analyzed and interpreted the data set, 
 Drafted, revised, and approved the manuscript for publication. 
 
Paper II (published in Malaria Journal): Recognition of Plasmodium falciparum 
mature gametocyte-infected erythrocytes by serum-antibodies of semi-immune 
adults and malaria exposed children from Gabon. 
 Contributed to the study design, 
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 Established and performed laboratory experiments, 
 Analyzed and interpreted the data set, 
 Drafted, revised, and approved the manuscript for publication. 
 
Paper III (published in the journal of Antimicrobial Agents and Chemotherapy): Effect 
of Fluorescent Dyes on In Vitro-Differentiated, Late-Stage Plasmodium falciparum 
Gametocytes. 
 Contributed to the study design, 
 Established gametocyte culture and adapted ATP-based bio-luminescence 
drug assay, 
 Performed laboratory experiments, 
 Analyzed and interpreted the data set, 
 Drafted, revised, and approved the manuscript for publication. 
 
Paper IV (published in the journal of Antimicrobial Agents and Chemotherapy): 
Antimalarial Activity of the Myxobacterial Macrolide Chlorotonil A. 
 Established gametocyte culture and adapted ATP-based bio-luminescence 
drug assay, 
 Performed laboratory experiments, 
 Analyzed and interpreted the data set from gametocyte drug assay, 
 Contributed in the draft and reviewed the manuscript for publication. 
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Life-span of in vitro differentiated 
Plasmodium falciparum gametocytes
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Abstract 
Background: The sexual stages (gametocytes) of Plasmodium falciparum do not directly contribute to the pathology 
of malaria but are essential for transmission of the parasite from the human host to the mosquito. Mature gameto-
cytes circulate in infected human blood for several days and their circulation time has been modelled mathematically 
from data of previous in vivo studies. This is the first time that longevity of gametocytes is studied experimentally 
in vitro.
Methods: The in vitro longevity of P. falciparum gametocytes of 1 clinical isolate and 2 laboratory strains was assessed 
by three different methods: microscopy, flow cytometry and reverse transcription quantitative real-time PCR (RT-
qPCR). Additionally, the rate of gametocytogenesis of the used P. falciparum strains was compared.
Results: The maximum in vitro lifespan of P. falciparum gametocytes reached almost 2 months (49 days by flow 
cytometry, 46 days by microscopy, and at least 52 days by RT-qPCR) from the starting day of gametocyte culture to 
death of last parasite in the tested strains with an average 50% survival rate of 6.5, 2.6 and 3.5 days, respectively. Peak 
gametocytaemia was observed on average 19 days after initiation of gametocyte culture followed by a steady decline 
due to natural decay of the parasites. The rate of gametocytogenesis was highest in the NF54 strain.
Conclusions: Plasmodium falciparum mature gametocytes can survive up to 16–32 days (at least 14 days for mature 
male gametocytes) in vitro in absence of the influence of host factors. This confirms experimentally a previous model-
ling estimate that used molecular tools for gametocyte detection in treated patients. The survival time might reflect 
the time the parasite can be transmitted to the mosquito after clearance of asexual parasites. These results underline 
the importance of efficient transmission blocking agents in the fight against malaria.
Keywords: Malaria, Clinical isolate, Gametocytogenesis, Gametocyte viability, Gametocyte circulation time, 
Gametocyte longevity, Exflagellation
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Background
Malaria is one of the most important infectious diseases, 
leading to approximately half a million annual deaths 
globally [1]. Among the different Plasmodium species 
that cause disease in humans, Plasmodium falciparum 
is the most virulent form and is responsible for most of 
the malaria morbidity and almost all malaria mortality 
in sub-Saharan Africa. The parasite is transmitted from 
the human host to the mosquito through mature sexual 
stages of the parasite (gametocytes) that circulate in 
peripheral blood. In the life cycle of P. falciparum, a cer-
tain percentage of asexual blood-stage parasites develop 
stochastically to gametocytes [2]. The immature forms 
(stage I–IV) sequester in internal organs [3, 4] for a maxi-
mum of 12 days [2], before developing to mature gameto-
cytes (stage V) that appear in the peripheral circulation 
and can be taken up by a blood-sucking female Anoph-
eles mosquito. Once in the mosquito’s midgut the sexual 
cycle continues leading to infective sporozoites in the 
salivary glands that render the mosquito infective to the 
next person it will bite.
As gametocytes are responsible for bridging the 
human/vector transmission of the parasite, studying 
their biology, development and viability or life span is of 
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Malaria Journal
*Correspondence:  janaheld@hotmail.de 
1 Institute of Tropical Medicine, University of Tübingen, Tübingen, 
Germany
Full list of author information is available at the end of the article
Page 2 of 10Gebru et al. Malar J  (2017) 16:330 
paramount importance for designing an effective trans-
mission-blocking strategy. Neglected in the past, this 
field is now getting more attention with a revival of inter-
est for the regional elimination and worldwide eradica-
tion of malaria [5, 6].
It has been shown earlier that even sub-microscopic 
densities of gametocytes in humans can establish mos-
quito infection [7, 8]. The chance of transmission of 
the parasite to the mosquito increases with the circula-
tion time of the parasite [9, 10]. Most anti-malarials are 
not effective against the transmission stages and only 
act indirectly by reduction of asexual stages or imma-
ture gametocytes [11, 12]. After an effective clearance 
of asexual parasites either by drugs or the immune 
response, the duration of gametocyte carriage depends 
on the sequestration and subsequent circulation time of 
gametocytes in the blood stream before the natural decay 
of the parasite happens. Once in the circulation, they 
remain infective for several days and may be even weeks, 
able to continue the transmission [9], but the exact time 
span is not known. Mathematical modelling in vivo after 
clearance of asexual stages by anti-malarial treatment 
in patients and subsequent detection by microscopy or 
molecular methods was so far the main method by which 
longevity of gametocytes was estimated. In these mod-
elling approaches, assumptions were made considering 
gametocyte conversion probability, sequestration periods 
and decay of gametocytes [2, 10, 13].
Even though transmission of the parasite to the mos-
quito is associated with circulation time [14, 15] and 
density of mature gametocytes [16, 17] in the infected 
person, this parameter is not well studied as it is techni-
cally difficult to measure gametocyte longevity in  vivo. 
The density of gametocytes in the circulation is often 
below the detection limit of commonly used methods 
and to follow in  vivo a single mature gametocyte when 
released from the site of sequestration to the peripheral 
circulation has never been achieved. However, in  vitro 
there is the possibility to follow gametocytes for their 
life span and evaluate their natural decay. In this study, 
the longevity of gametocytes was assessed in  vitro by 
three different methods: microscopy, flow cytometry and 
reverse transcription quantitative real-time polymerase 
chain reaction (RT qPCR). In addition, the rate of game-
tocytogenesis was evaluated in the different P. falciparum 
strains by microscopy, to characterize variation in game-
tocyte development.
Methods
Gametocyte culture
Gametocyte culture was initiated from an asexual cul-
ture of 1 clinical isolate (JH013) and 2 laboratory strains 
(3D7 and NF54) of P. falciparum. The clinical isolate 
(JH013) was selected from a previous study conducted in 
Lambaréné, Gabon [18]. The isolate was collected from 
a patient presenting with P. falciparum mono-infection 
and preserved in glycerolyte at −196  °C until cultur-
ing. JH013 and the P. falciparum laboratory strains 3D7 
(Malaria Research and Reference Reagent Resource 
(ATCC, Virginia, USA) and NF54, isolated from a vol-
unteer inoculated with PfSPZ Challenge for controlled 
human malaria infection (Sanaria Inc, Rockville, MD, 
USA) [19], were kept in asexual culture at 5% haemato-
crit in RPMI 1640 supplemented with 25  mM HEPES, 
28 mM NaHCO3, 50 μg/mL gentamicin, 0.5% w/v Albu-
max II, 2.4 mM l-glutamine, and 0.14 mM hypoxanthine 
at 5%  CO2 and 5%  O2. Naïve serum (5%) was added for 
the cultivation of the asexual parasites of the clinical iso-
late. The medium was replaced every 24 h.
Gametocyte culture was performed as described before 
[11] with modifications: the culture was started from 
asexual parasites that were kept in a continuous culture 
with sorbitol synchronization twice weekly. The same 
culture medium was used for the gametocyte develop-
ment as for the asexual culture except the addition of 
5% naïve serum for both clinical and laboratory strains. 
The culture was initiated with 9% haematocrit and 0.5% 
parasitaemia in 20  mL total volume and was kept in 
a 5%  O2/CO2 atmosphere at 37  °C with daily change of 
medium without parasite dilution. In the second week, 
the volume of medium was doubled and thereby the 
haematocrit reduced to 4.5%. On days 11–15 and from 
day 19 on every 5  days for 2 consecutive days, cultures 
were treated with 50  mM N-acetyl-d-glucosamine (MP 
Biomedicals GmbH, Santa Ana, CA, USA) to remove or 
suppress asexual parasites to avoid emergence of new 
gametocytes. The culture was followed until all gameto-
cytes were judged as dead with daily change of complete 
medium without any purification or enrichment step.
Assessment of gametocyte longevity
Microscopy, flow cytometry and RNA-based RT-qPCR 
were used to assess the longevity of gametocytes of dif-
ferent strains of P. falciparum. Day 0 is the starting day 
of gametocyte culture and the culture was followed 
until the last positive signal representing a gametocyte 
detected by the respective technique. Longevity after 
reaching maturity represents the estimated in vivo circu-
lation time as only mature gametocytes circulate freely in 
the blood. This was calculated by subtracting the number 
of days needed to reach peak gametocytaemia (see day 
of peak gametocytaemia in Table 1). On the day of peak 
gametocytaemia all gametocytes in the respective culture 
reached maturity (stage V), as checked by microscopy. 
The 50 and 10% survival rate of mature gametocytes was 
also calculated starting with the day of peak parasitaemia. 
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After initiation of gametocytogenesis a sample was taken 
on days 3, 5, 8, 10, 12, 18, 20, 22, 27, 33, 35, 38, 40, 43, 46, 
49, and 52 and analysed by microscopy, flow cytometry 
and RTqPCR.
Assessment of gametocyte longevity by microscopy
Viability of gametocytes was assessed microscopically 
in two parasite strains, the NF54 laboratory strain and 
JH013 clinical isolate by evaluating the morphology of 
parasites in a Giemsa-stained thin blood smear. Gameto-
cytes were classified either as viable (normal intact mor-
phology of mature gametocytes) or dead (deformed cells 
with a decrease in width, a thin needle-like appearance or 
degraded cytoplasmic content). Parasitaemia of mature 
gametocytes ((number of mature gametocyte infected 
erythrocytes/number of erythrocytes) × 100) was deter-
mined by two trained and qualified readers blinded to 
each other and the slide identification (ID). Samples were 
declared negative if no intact and mature gametocytes 
were seen in 20,000 erythrocytes. In case of discordant 
results a third reading was performed.
To verify viability, an exflagellation assay (incubation 
for 20 min in exflagellation medium supplemented with 
xanthurenic acid as described earlier [20]) was addition-
ally performed on days 17, 18, 19, 20, 22, 27, 33, 35, and 
38 to assess exflagellation of male gametocytes in NF54 
and JH013.
Assessment of gametocyte longevity by flow cytometry
Viability and life span of gametocytes of P. falciparum 
isolates (3D7, NF54, JH013) was assessed also by hydro-
ethidine (HE) staining evaluated by flow cytometry to 
measure metabolic activity. HE staining has been used 
earlier in a flow cytometric gametocyte drug assay 
[21]. HE staining (Polysciences Europe GmbH, Eppel-
heim, Germany) was performed at a final concentra-
tion of 50 µg/mL in medium for 20 min at 37  °C in the 
dark before analysis by flow cytometry (BD FACS Canto 
II) with the FACSDiva software version 6.1.2 (BD Bio-
sciences, San Jose, USA). Metabolically active parasites 
convert HE to ethidium that interacts with the parasites’ 
nucleic acids showing red fluorescence emission when 
excited (see panel B of Additional file 1: Figure S1). The 
result is expressed as the percentage of positive fluo-
rescent cells (PPFC) in 50,000 erythrocytes. As a nega-
tive control, uninfected erythrocytes (incubated with 
medium in the same way as the culture) were used for 
gating (see panel A of Additional file  1: Figure S1). The 
gametocyte culture was followed until no positive signal 
above the negative control could be seen after HE stain-
ing. After day 15, a control slide was additionally done 
and read by microscopy to exclude presence of asexual 
parasites.
Assessment of gametocyte longevity by reverse 
transcription quantitative PCR
RNA extraction
On the sampling days, 40  µL of erythrocytes was taken 
out of the culture for molecular detection of gametocytes 
and was added to 100 µL Trizol reagent (Life Technolo-
gies GmbH, Darmstadt, Germany) for RNA stabilization 
and stored at −80  °C until RNA extraction. RNA puri-
fication was done automated on the QIAsymphony SP 
(QIAGEN GmbH, Hilden, Germany) using the QIAsym-
phony RNA Kit (QIAGEN GmbH, Hilden, Germany) 
and RNA CT 400 protocol provided with the instrument. 
Before purification, frozen samples were thawed and vor-
texed followed by an incubation at room temperature 
Table 1 Summary of in vitro gametocyte longevity data evaluated by three viability assays from cultures of one Plasmo-
dium falciparum clinical isolate and two laboratory strains
a Mid and mature gametocyte marker [23]
b Circulation time is calculated by subtracting the number of days needed to reach peak gametocytaemia
c On the day of peak gametocytaemia all gametocytes in the respective culture have reached maturity (stage V)
Plasmodium falciparum Gametocyte longevity in days: mean (range)
Microscopy Flow cytometry RT-qPCR
Pfs25 PF14_0367a
3D7 – 46 (43–49) – –
NF54 46 49 (48–50) >52 >52
JH013 39 (38–40) 45 (43–49) >52 46
Average number of days of gametocyte culture to reach peak gametocytaemia (maturation)c 20.5 16 19 19
Mature gametocytes 50% survival rate (days) 2.6 6.5 4.5 2.5
Mature gametocytes 10% survival rate (days) 10 12 13.3 10.4
Mature gametocyte circulation time (days)b 18–26 16–24 31–32 26–31
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(RT) for 5  min. Then 20  µL chloroform (Sigma-Aldrich 
Chemie GmbH, Munich, Germany) was added to the 
homogenized mixture and shaken vigorously for 15 s and 
incubated for 3 min at RT before centrifugation at 4  °C 
for 15 min at 11,500 rpm. The upper aqueous phase was 
transferred to 2-mL sample tubes (Sarstedt, Numbrecht, 
Germany) and the volume adjusted to 400 µL with buffer 
RTL Plus (Qiagen) and loaded onto the QIAsymphony 
SP. All samples were eluted in 100  µL elution buffer in 
96-well plates (Qiagen). Gametocyte density calibration 
standards were generated from tenfold serial dilution of 
gametocytes  (107–10) in 40 µL of erythrocytes.
Molecular detection of Plasmodium falciparum 
gametocytes by RT-qPCR
Plasmodium falciparum gametocytes (NF54 and 
JH013) were quantified by RT-qPCR analysed by the 
 LightCycler® 480 Instrument II (Roche Diagnostics, 
Mannheim, Germany). Gametocyte-specific targets 
published earlier were used to measure transcript levels 
of Pfs25 mRNA [22] and Pf14_0367 [23] with modifica-
tions. Custom one-step RT-qPCR assay was performed 
using Taqman RNA-to-CT™ 1-Step kit (Thermo Fisher 
Scientific). The reaction consisted of 1  ×  Taqman RT-
qPCR mix, 1 × Taqman enzyme mix, 150 nM probe, and 
400 nM of each primer and 2.5 µL of RNA extract. The 
thermal conditions consisted of reverse transcription 
(48 °C for 20 min), enzyme activation (96 °C for 10 min), 
and two-temperature cycling step (95  °C for 15 s, 62  °C 
for 1  min, for 45 cycles). The amplification curves were 
assessed for true amplification and the quantification 
cycle value  (Cq) was automatically calculated by the sec-
ond derivative maximum method integrated in the Light-
Cycler 480 software (version 1.5.1.62). The positivity of 
the amplification was defined by  Cq value less than 40 in 
at least two technical replicates. The gametocyte density 
was derived from extrapolation of the  Cq value obtained 
from the standard curve (Additional file  2: Figure S2). 
Primer and probe sequences are listed in Additional 
file 3: Table S1 and PCR conditions in Additional file 4: 
Table S2. All samples including the gametocyte standards 
were tested in triplicate in the presence of positive and 
negative (non-template and non-RT) controls.
In vitro gametocytogenesis of different strains 
of Plasmodium falciparum
In order to compare the rate of gametocytogenesis of 
different strains of P. falciparum, the same culture con-
ditions were used for gametocytes as described above. 
After removal of asexual parasites by the application of 
N-acetyl-d-glucosamine between days 11 and 15 of the 
gametocyte development, the culture was purified first 
by NicoPrep 1.077 cushions (AXIS-SHIELD PoC AS, 
Oslo, Norway) and later by LD-MACS magnetic col-
umns (Miltenyi Biotec, Gladbach, Germany) resulting in 
highly purified (above 95% stage V) gametocytes (Addi-
tional file 5: Figure S3). This purification procedure was 
not applied to the cultures used for the longevity assay. 
Parasites were kept at 37 °C during the whole procedure 
to avoid exflagellation, as described earlier [24]. The effi-
ciency of gametocytogenesis of three different strains of 
P. falciparum was assessed: the laboratory strains 3D7 
and NF54 and 1 clinical isolate (JH013) from Lambaréné, 
Gabon in complete culture medium in the presence or 
absence of 5% serum. The parasites of all the three strains 
were cultured in 75-cm2 flasks with a starting volume of 
20  mL gametocyte culture that contained 2  mL eryth-
rocyte pellet. Gametocyte yield was determined after 
15 days of culture by counting the purified stage V game-
tocytes using a Neubauer improved cell counting cham-
ber. The tests were done three times in duplicate for each 
strain and the mean was determined.
Statistical analysis
Descriptive statistics were calculated with GraphPad 
Prism version 6.0 (GraphPad Software, San Diego, CA, 
USA) for determining mean, percentages, standard devi-
ation and plotting of graphs. Excel 2013 and GraphPad 
Prism 6 was used for the calculation of gametocytaemia 
of microscopic and flow cytometric data. A sample was 
declared positive by flow cytometry if the percentage 
gated cells positive for HE was above the negative control 
(erythrocytes cultured in complete culture medium in the 
incubator). PCR data were analysed by Excel and gameto-
cytaemia was extrapolated with the help of a gametocyte 
standard curve with known parasitaemia. To estimate the 
50 and 10% survival rate of gametocytes, Excel was used 
to develop a linear regression equation using the log-
transformed data of the different viability assays starting 
on the day of highest parasitaemia. Mann–Whitney test 
and Wilcoxon matched-pairs signed rank test were used 
in GraphPad Prism 6, for non-parametric analysis of the 
difference in the gametocytogenesis rate among the dif-
ferent isolates in the presence or absence of serum.
Results
Longevity of gametocytes was assessed by three different 
viability methods.
Microscopic reading
The gametocytes appeared viable with intact cytoplasm 
for several weeks after reaching stage V (Fig.  1). Live 
gametocytes were detected on average for a maximum 
of 39 and 46  days after initiation of gametocytogen-
esis in JH013 and NF54, respectively. The longevity 
after reaching maturity was 18–26  days. The mean 50 
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and 10% survival rate were 2.6 and 10  days, respec-
tively. The highest number of gametocytes can be seen 
on days 20–22. The percentage of live, mature, gameto-
cyte-infected erythrocytes for the different days of the 
gametocyte culture evaluated by the blinded readers is 
shown in Fig. 2. The last viable gametocyte was seen on 
days 40 and 46 for JH013 and NF54 P. falciparum strain, 
respectively.
Fig. 1 Microphotograph of Giemsa-stained thin smears of Plasmodium falciparum gametocyte (NF54) culture on different days of gametocyte 
development (magnification ×1000). N-Acetyl-glucosamine has been added on days 11–15 and from day 19 on every 5 days for 2 consecutive days
Fig. 2 Longevity of gametocytes evaluated microscopically by morphological assessment. Viability of live gametocytes (1 clinical isolate and 1 
NF54 laboratory strain) was assessed by microscopy. a The percentage of mature gametocytes in erythrocytes (parasitaemia) from days 12 to 52 
of gametocyte culture. Values indicate the mean percentage (and SD) of live gametocytes counted by two qualified microscopists for the separate 
experiments. The days on which exflagellation was detected is indicated by a white/blue star at the bottom of the bar graph. a Also shows a scatter 
chart with a trend line and equation made using log.transformed gametocytaemia data from microscopy displayed on the y-axis of the graph. b 
Giemsa-stained thin smears of gametocyte culture with live and dead gametocytes. Log. logarithmic, SD standard deviation
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Exflagellation assay
Exflagellation of male gametocytes was observed repro-
ducibly until day 33, whereas from day 35 on no exflag-
ellated males could be detected (Fig. 2). The experiment 
was repeated three times.
Flow cytometry
Analysis of flow cytometry data measuring HE stain-
ing of P. falciparum gametocytes showed a longevity of 
43–49  days in the tested clinical isolate and laboratory 
strains with an average 50% survival rate of 6.5 days, 10% 
survival rate of 12 days and peak gametocytaemia on day 
16, following the removal of asexual parasites (Fig. 3). On 
day 12 there were still asexual parasites left in the culture 
that were also stained by HE. Therefore, these data are 
excluded from Fig.  3 to avoid confusion. The estimated 
circulation time (longevity after reaching stage V) was 
16–24 days.
Molecular detection of Plasmodium falciparum 
gametocytes by RT-qPCR
RT-qPCR was used to assess a marker for mature (Pfs25 
[22]) and a marker for both middle and mature stage 
(PF14_0367) [23]) gametocytes. The peak gametocytae-
mia was higher in NF54 gametocytes compared to JH013 
(Fig.  4). Gametocyte longevity was longer when evalu-
ated by PCR compared to microscopy and flow cytom-
etry. For JH013, the PF14_0367 signal was detected until 
day 46 and the Pfs25 signal until day 52. Both markers 
were detectable until day 52 in NF54. The mature game-
tocyte 50 and 10% survival rate were on average 3.5 and 
12 days, respectively. Peak parasitaemia was recorded on 
days 18 and 20 and the estimated circulation time was 31 
and 26–32 days for NF54 and JH013, respectively.
In vitro gametocytogenesis
Rate of gametocytogenesis was assessed in three differ-
ent parasite lines (3D7, NF54 and JH013) of P. falciparum 
in  vitro after purifying mature gametocytes (Additional 
file  5: Figure S3). The highest yield of gametocytes was 
recorded in NF54 followed by the clinical isolate (JH013). 
The pattern of parasitaemia peak and decline was simi-
lar in all gametocyte cultures. Serum supplementation 
enhanced the gametocyte yield in all strains (Fig.  5). 
There was no statistically significant difference in game-
tocyte yield among the different strains and between the 
cultures with or without serum supplementation.
A summary of the longevity data evaluated by the dif-
ferent methods is given in Table 1, showing that analysis 
by RTqPCR was the most sensitive method, revealing the 
Fig. 3 In vitro longevity of Plasmodium falciparum gametocytes of 3D7, NF54 and one clinical isolate (JH013) of hydroethidine (HE) stained and 
analysed by flow cytometry. Mean (and SD) maximum longevity of gametocytes is shown in days. Viability of gametocytes is assessed by flow 
cytometry measuring the percentage of positive fluorescent cells (PPFC) of 50,000 erythrocytes gated against negative control (uninfected erythro-
cytes stained by HE). All strains were tested at least three times. The figure also shows a scatter chart with a trend line and equation made using log.
transformed gametocytaemia data from flow cytometry displayed on the y-axis of the graph. Log. logarithmic, SD standard deviation
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longest life span for gametocytes, followed by analysis by 
flow cytometry and microscopy. The strain NF54 had the 
longest life span by all methods and it was more prone 
for gametocyte commitment compared to the other two 
strains tested.
Discussion
Density, sex ratio and life span of stage-V gametocytes of 
P. falciparum are the most important factors determin-
ing the probability of transmission to the mosquito. The 
maximum life span of gametocytes was explored here 
for the first time in vitro. Viability of gametocytes ranged 
from 39 to 52  days (16–32  days after reaching maturity 
considering peak gametocytaemia as the day of matura-
tion) depending on the different measurement methods 
used, with little variability between the different para-
site strains (Table 1). This time-span corresponds to the 
in vivo gametocyte carriage or the sum of sequestration 
and circulation time of the parasite in an infected per-
son. Mature gametocytes (stage V), that freely circulate 
in the peripheral blood, are developed latest after 12 days 
[2]. Based on the ex-flagellation assay, at least 14 days of 
longevity was recorded for mature male gametocytes. By 
the protocol used here, gametocytes are generated during 
the first few cycles of asexual culture and therefore age of 
gametocytes or the day of maturity is not the same for the 
whole gametocyte population of one culture. However, it 
was observed that all gametocytes matured at the day of 
peak gametocytaemia, and therefore gametocyte peak 
was used as the day of gametocyte maturity to calculate 
longevity of mature gametocytes (estimated in  vivo cir-
culation time). When subtracting this maturation time, 
the circulation time estimated here is 16–32 days. It was 
observed that some gametocytes were already mature 
Fig. 4 Number of gametocytes/µL of JH013 and NF54 on the different days after culture initiation measured by RT-qPCR. Quantification of test 
sample was done with the help of a standard curve. The previously reported gametocyte markers (PF14_0367 [23] and Pfs25 [22]) were used. Y axis 
shows the mean and SD. SD standard deviation. The figure also shows a scatter chart with a trend line and equation made using log.-transformed 
gametocytaemia data displayed on the y-axis of the graph. Log. logarithmic
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before peak gametocytaemia and the real life span or 
circulation time could be a bit longer than provided. In 
previous in  vivo studies that assessed gametocytaemia 
by microscopy, the circulation time was estimated to 
be at maximum 24 [9] and 22.2  days (with mean circu-
lation time 6.4  days) [2]. The differences in longevity to 
the present study likely result from the influence of host 
factors in in  vivo studies but also from assumptions of 
mathematical modelling that may be incorrect, as well 
as the limit of detection of gametocytaemia by micros-
copy. It was observed in the here-presented in vitro assay 
that peak gametocytaemia is not yet reached on day 15, 
indicating the presence of some immature stages on this 
day. Commitment of gametocytes occurs not only on 
the first day of starting gametocyte culture but during 
the first 2–3 cycles of asexual multiplication. This might 
slightly affect the longevity estimate that is provided here, 
as some gametocytes might be some days younger than 
other gametocytes. To account for this the longevity of 
mature gametocytes (estimated circulation time) was cal-
culated from day of peak gametocytaemia measured by 
the different approaches. The 50 and 10% survival rate is 
also calculated starting from day of peak-parasitaemia.
Another study estimated the maximum duration of 
gametocyte carriage (corresponding to the sum of in vivo 
sequestration and circulation time) to be 55  days based 
on molecular detection of Pfs25 and mathematical mod-
elling [10]. Longevity of gametocytes reported in this 
study is similar with the current in vitro data presented 
here. Gametocytes were detected up to 52  days in cul-
ture by PCR when analysing the female gametocyte spe-
cific marker Pfs25. For PF14_0367 the signal was slightly 
weaker and in the tested clinical isolate (JH013) it was no 
longer detectable after day 46. The difference of the two 
markers is most probably due to the higher copy num-
ber and expression of Pfs25 at the gametocyte stage com-
pared to PF14_0367 [23]. Slight differences in longevity 
of male and female gametocytes could also be the reason; 
however, no difference was seen in an earlier publication 
between male and female gametocyte longevity or mor-
tality in vivo [9].
If these in vitro reared gametocytes are actually able to 
infect mosquitoes cannot be answered by this approach. 
However, in the exflagellation assay presented here, the 
male gametocytes were able to exflagellate for at least 
2  weeks after reaching maturity. Similarly, Smalley and 
Sinden have reported that exflagellation of microgametes 
and infectivity to mosquitoes can take place for 3 weeks 
[9]. In line with this, a recent report showed in vivo the 
persistence of gametocytaemia following treatment with 
atovaquone–proguanil. This was later interrupted by 
primaquine treatment after 21 days of consistent game-
tocyte detection in a participant in a controlled human 
malaria infection trial [25].
One has to be careful to translate in  vitro data to the 
in vivo situation as there are several contradictory factors 
influencing the longevity of gametocytes in vivo. On the 
one hand, the immune response of the host is negatively 
influencing longevity of the parasite, whereas on the 
other hand, the nutrition status might be more favoura-
ble for the parasite in the human host than in the culture 
flask. The in vitro culture shows longevity of gametocytes 
excluding the host factors.
Even though gametocytes have a long life-span in vitro, 
their half-life (50% survival rate) was short (2.6–6.5 days), 
similar to the result shown in a previous in  vivo study 
(2.4  days) [9]. The peak gametocytaemia is followed by 
a steady decline in parasitaemia with few gametocytes 
remaining for several weeks, and around 10% surviving 
for 10–12 days after peak gametocytaemia. After day 40, 
on average less than 5% of the gametocytes remained 
viable. Studies have shown that if gametocytes remain 
viable, a small number of gametocytes (sub-microscopic 
level) is sufficient for transmission [7, 8]. These findings 
underline the importance of development of efficacious 
gametocidal drugs and its timely usage, especially if elim-
ination and even eradication of malaria is the aim.
In this study, the NF54 strain of P. falciparum used 
for experimental human infection was more prone to 
develop into gametocytes followed by JH013 and 3D7. 
Similar to this report, it was shown earlier that the 
Fig. 5 In vitro gametocytogenesis of Plasmodium falciparum 3D7, 
NF54 and JH013 cultured in complete medium in presence and 
absence of serum. The results shown represent the mean of at least 
three experiments. Mean and standard deviations are presented. The 
gametocyte yield was measured on day 15 after start of gametocyte 
culture with a starting volume of 20 mL medium with 2 mL erythro-
cyte pellet in 75-cm2 flasks. SD standard deviation
Page 9 of 10Gebru et al. Malar J  (2017) 16:330 
gametocyte yield varies between different parasite lines 
[26]. Many factors are considered to influence sexual 
commitment of the parasite including genetic variation, 
environmental factors [27] and long-term in  vitro cul-
ture [26, 28]. The same type of medium, erythrocytes and 
serum (in those cultures supplemented with serum) was 
used to avoid modulation of gametocytogenesis by cul-
ture conditions [28].
Serum supplementation in the gametocyte culture 
improved the gametocyte yield in all three strains of P. 
falciparum tested. It was previously reported that serum 
taken from infected individuals increased the sexual 
conversion rate of P. falciparum [29]. Here it is shown 
that supplementation of serum from non-infected per-
son also improves the gametocyte yield in  vitro. The 
enhanced yield of gametocytes could also be due to an 
increased multiplication of the asexual parasites of the 
gametocyte culture when serum is used as reported ear-
lier [29].
Conclusions
Transmission of P. falciparum to mosquito depends on 
mature viable gametocytes in the peripheral blood of 
the host [30]. The in  vitro life span (estimated in  vivo 
circulation time) of mature gametocytes was 2–4 weeks 
in this study. These findings may help to design inter-
ventions to prevent transmission as part of elimination 
programs and containment of resistant P. falciparum 
isolates.
Additional files
Additional file 1: Figure S1. Flow cytometry analysis of Plasmodium 
falciparum (JH013) parasites. Samples were stained with hydroethidine 
(HE) and analysed by flow cytometry. Panel A shows the negative control. 
The erythrocytes are cultured in complete culture medium and stained 
with HE. Panel B shows the gating strategy and percent-infected eryth-
rocytes of a sample taken from gametocyte infected erythrocytes (from 
gametocyte culture).
Additional file 2: Figure S2. Standard curves used for gametocyte 
quantification by RTqPCR. Dilution series of in vitro cultivated gameto-
cytes were analysed by PF14_0367 and Pfs25. Standard curves were gen-
erated performing linear regression using the  Log10 transformed number 
of gametocytes and the mean and SEM of the quantification cycles  (Cqs) 
of triplicates. SEM: standard error of the mean.
Additional file 3: Table S1. Primer and probe sequences used in 
gametocyte-specific RTqPCR.
Additional file 4: Table S2. TaqMan One-Step Real-Time RT-PCR (RNA-
to-Ct™ 1-Step Kit) PCR mix and cycling conditions.
Additional file 5: Figure S3. Microphotograph of Giemsa-stained thin 
smears showing gametocyte culture on day 15 before (A) and after (B) 
purification (magnification ×1000). Uninfected erythrocytes and remain-
ing asexual parasites were removed by the two-step purifications for the 
in vitro measurement of gametocytogenesis of 3D7, NF54 and one clinical 
isolate (JH013).
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12936_2017_1986_MOESM1_ESM.tif Additional file 1: Figure S1. Flow cytometry analysis 
of Plasmodium falciparum (JH013) parasites. Samples were stained with hydroethidine (HE) and 
analysed by flow cytometry. Panel A shows the negative control. The erythrocytes are cultured 
in complete culture medium and stained with HE. Panel B shows the gating strategy and percent-
infected erythrocytes of a sample taken from gametocyte infected erythrocytes (from gametocyte 
culture).  
 
 
 
 
 
 
 
 
 
 
 
12936_2017_1986_MOESM2_ESM.tif Additional file 2: Figure S2. Standard curves used for 
gametocyte quantification by RTqPCR. Dilution series of in vitro cultivated gametocytes were 
analysed by PF14_0367 and Pfs25. Standard curves were generated performing linear regression 
using the Log10 transformed number of gametocytes and the mean and SEM of the quantification 
cycles (Cqs) of triplicates. SEM: standard error of the mean.  
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Table S1. Primer and probe sequences used in gametocyte-specific RTqPCR. 
Species Target gene Primer name Primer sequence (5’->3’) 
P. falciparum Pfs25 1 Pfs25_Fwd GAC TGT AAA TAA ACC ATG TGG AGA 
Pfs25_Rev CAT TTA CCG TTA CCA CAA GTT A 
Pfs25_Probe LC640 - AGA TGG AAA TCC CGT TTC ATA CGC TTG T 
PF14_0367 1 
(mid-late 
gametocytes)  
MG_Fwd GTTACATTTCGACCCAGCATAAATT 
MG_Rev GTTACATTTCGACCCAGCATAAATT 
MG_Probe VIC - CAG TGC ATA TTG TTG CCT GT - MGBNFQ 
1 The primer and probe sequences of mid-late stage gametocyte marker (PF14_0367) 
were previously published (Joice et al 2013), whereas we have designed a new 
sequences for the Pfs25 marker. 
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Table S2. TaqMan One-Step Real-Time RT-PCR (RNA-to-Ct™ 1-Step Kit) PCR mix 
and cycling conditions. 
A. RT-qPCR Reaction Mix 1 
PCR mix Volume (µL) 
TaqMan® RT-PCR Mix (2✕) 5 
Forward primer 0.4 
Reverse primer 0.4 
TaqMan probe 0.15 
RNA template 2.5 
RNase-free H2O 1.3 
TaqMan® RT Enzyme Mix (40✕) 0.25 
Total                 10 
 
B. RT-qPCR Thermal cycling conditions 2   
Stage Step Temperature Time 
Holding Reverse transcription 48°C 20  minutes 
Holding Polymerase activation 96°C 10 minutes 
Cycling (45x) Denaturation 95°C 15 seconds 
Annealing/Extension 62°C 1 minute 
Holding Cooling 48°C 10 seconds 
 
1 The reaction was prepared in a PCR cabinet and the mix was dispensed to the 384 
wells using a Qiagen QIAgility High-Precision Automated PCR System.    
2 The PCR was run using the LightCycler® 480 Real-Time PCR System (Roche 
Diagnostics, Mannheim, Germany) and all samples with Ct value ≤40 were considered 
positive.  
 
12936_2017_1986_MOESM5_ESM.tif Additional file 5: Figure S3. Microphotograph of 
Giemsa-stained thin smears showing gametocyte culture on day 15 before (A) and after (B) 
purification (magnification ×1000). Uninfected erythrocytes and remaining asexual parasites 
were removed by the two-step purifications for the in vitro measurement of gametocytogenesis 
of 3D7, NF54 and one clinical isolate (JH013).  
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Recognition of Plasmodium falciparum 
mature gametocyte-infected erythrocytes 
by antibodies of semi-immune adults 
and malaria-exposed children from Gabon
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Abstract 
Background: Transmission of malaria from man to mosquito depends on the presence of gametocytes, the sexual 
stage of Plasmodium parasites in the infected host. Naturally acquired antibodies against gametocytes exist and 
may play a role in controlling transmission by limiting the gametocyte development in the circulation or by inter-
rupting gamete development and fertilization in the mosquito following ingestion. So far, most studies on antibody 
responses to sexual stage antigens have focused on a subset of gametocyte-surface antigens, even though inhibitory 
Ab responses to other gametocyte antigens might also play a role in controlling gametocyte density and fertility. 
Limited information is available on natural antibody response to the surfaces of gametocyte-infected erythrocytes.
Methods: Ab responses to surface antigens of erythrocytes infected by in vitro differentiated Plasmodium falciparum 
mature gametocytes were investigated in sera of semi-immune adults and malaria-exposed children. In addition, 
the effect of immunization with GMZ2, a blood stage malaria vaccine candidate, and the effect of intestinal helminth 
infection on the development of immunity to gametocytes of P. falciparum was evaluated in malaria-exposed chil-
dren and adults from Gabon. Serum samples from two Phase I clinical trials conducted in Gabon were analysed by 
microscopic and flow-cytometric immunofluorescence assay.
Results: Adults had a higher Ab response compared to children. Ab reactivity was significantly higher after fixation 
and permeabilization of parasitized erythrocytes. Following vaccination with the malaria vaccine candidate GMZ2, 
anti-gametocyte Ab concentration decreased in adults compared to baseline. Ab response to whole asexual stage 
antigens had a significant but weak positive correlation to anti-gametocyte Ab responses in adults, but not in chil-
dren. Children infected with Ascaris lumbricoides had a significantly higher anti-gametocyte Ab response compared to 
non-infected children.
Conclusion: The current data suggest that antigens exposed on the gametocyte-infected red blood cells are recog-
nized by serum antibodies from malaria-exposed children and semi-immune adults. This anti-gametocyte immune 
response may be influenced by natural exposure and vaccination. Modulation of the natural immune response to 
gametocytes by co-infecting parasites should be investigated further and may have an important impact on malaria 
control strategies.
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Background
Malaria remains a major global public health problem 
affecting hundreds of millions of people annually, mainly 
in sub-Saharan Africa. Each year approximately half a 
million people die, mostly children younger than 5 years 
[1]. Gametocytes, the sexual stage of the parasites, are 
essential for transmission of the parasite from man to 
mosquito. Malaria transmission can be interrupted by 
drug treatment affecting gametocytes [2, 3], causal chem-
oprophylaxis, vector control as well as the acquisition of 
immunity to sexual stage parasites by the human host [4, 
5].
Transmission blocking interventions that target game-
tocyte development and gamete fertilization are con-
sidered an essential part of malaria control, especially 
if containment or eradication of the disease is the aim. 
Transmission blocking vaccines (TBVs) would have a 
great public benefit in malaria-endemic countries by 
breaking the life cycle and decreasing the number of new 
infections. In addition, it is assumed that TBVs could 
help in containing the spread of parasites resistant to 
drugs or malaria vaccine components directed against 
asexual blood stage or pre-erythrocytic stages [6, 7]. To 
better understand immunity against the sexual stage of 
the plasmodial life cycle and for the design and develop-
ment of TBVs, profiling the response to mature gameto-
cytes is of relevance.
Antibodies (Abs) are important mediators of sexual 
stage immunity against Plasmodium and other apicompl-
exan parasites [8–12]. Such Abs can affect malaria trans-
mission either by inhibiting gametocyte development [5] 
or by directly affecting viability of mature sexual stages 
[13–15]. The latter might happen within the body or once 
they are ingested by mosquitoes [5, 16–18], e.g. through 
opsonization of gametes followed by phagocytosis [12]. 
In malaria-endemic areas, the age-dependent decline of 
the duration of gametocyte carriage [19, 20] is most likely 
due to an increase in gametocyte exposure and develop-
ment of sexual stage specific immune responses, in paral-
lel to the asexual immunity acquired with age [21].
Indirectly, immune responses to asexual stage anti-
gens may decrease transmission by limiting the number 
of asexual parasites that develop to gametocytes [21], 
similar to the decrease of gametocytogenesis that results 
from the elimination of asexual infections by drugs [22]. 
However, development of sexual-stage immunity is dif-
ferent from the immune response directed to asexual 
stage antigens [13, 15]. Gametocytes have distinct gene 
expression patterns [23] and proteomic profiles [24] 
compared to asexual stages. Similarly early and late stage 
gametocytes differ; for example, the latter have a com-
paratively low representation of active export machinery 
proteins. However, some overlaps are expected in the 
proteomic profiles and exported proteins between the 
different stages of the parasite’s life cycle [24].
Naturally acquired sexual-stage antibodies are pro-
duced against gametocyte-infected erythrocyte surface 
antigens or gamete-specific antigens in the circulation 
and also against mosquito-stage parasites that act follow-
ing ingestion of the parasite [25]. There are only few stud-
ies on natural immune responses to gametocyte-infected 
erythrocyte surface antigens. Saeed et  al. [15] showed 
that 34% of Gambian children had plasma antibodies 
recognizing stage V gametocyte-infected erythrocytes 
in vitro, with no recognition of stages I–IV. In the same 
study Abs to gametocyte surface antigens were associated 
with lower gametocyte densities indicating the impor-
tance of Abs in reducing gametocyte carriage. Most other 
studies on immune responses to sexual stage antigens 
have focused on few specific antigens, mainly the TBV 
candidates Pfs230 [18, 26–31] and Pfs48/45 [18, 27–32]. 
The association of Ab response to these single antigens 
and transmission reducing activity is not consistent. 
After testing antibody response to both antigens, some 
authors reported a correlation of transmission reduction 
with both antigens [31], while others found associations 
only with Pfs230 [18, 28] or only with Pfs48/45 [29, 30]. 
Even though correlation might be confounded by expo-
sure history to earlier malaria infections, these results 
suggest that Ab responses to other gametocyte-specific 
antigens may play an additional role in controlling trans-
mission [5]. Here, Ab responses to gametocyte-infected 
erythrocyte surface antigens were measured in individu-
als from a malaria-endemic country (Gabon).
In the present study, the concentration of anti-game-
tocyte Abs against in  vitro differentiated mature game-
tocytes of one Plasmodium falciparum clinical isolate 
and one laboratory strain (NF54) was measured by flow 
cytometric immunofluorescence assay (IFA) in sera from 
malaria-exposed children and semi-immune adults. Since 
exposure to asexual blood stage antigens and co-infec-
tion with other highly prevalent parasites may modulate 
immune responses [33, 34], here the anti-gametocyte 
responses were related to infection status with intestinal 
helminths. Assuming a reduced anti-gametocyte anti-
body response after vaccination with a malarial vaccine, 
Keywords: Malaria, Transmission blocking, Plasmodium falciparum, Clinical isolates, Helminths, Ascaris lumbricoides, 
Trichuris trichiura, GMZ2, Immune modulation
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additionally the anti-gametocyte antibody response to 
antibodies induced by vaccination was related with the 
asexual blood stage vaccine candidate GMZ2, a recombi-
nant fusion protein of P. falciparum glutamate-rich pro-
tein (GLURP) and merozoite surface protein 3 (MSP3) 
[35]. Therefore, the collected serum samples during the 
GMZ2 trials were used to investigate this in depth.
Methods
Study samples and sources
Gametocyte recognition of antibodies were investigated 
in adults and children who had a different history of 
exposures to malaria and infection status with intestinal 
helminths. The serum samples analysed in the current 
investigation are from two studies [36, 37] conducted 
between July 2007 and October 2008 at the Centre de 
Recherches Médicales de Lambaréné (CERMEL), Lam-
baréné in Gabon. The two sets of serum samples were 
from Phase I clinical trials designed to assess safety and 
immunogenicity of GMZ2, an experimental blood-stage 
malaria vaccine candidate, in malaria-exposed adults and 
children, respectively [36, 37], which shows partial effi-
cacy [38].
As part of the GMZ2 trials, samples were collected 
from 30 children aged 1–5  years [36] and 40 semi-
immune adults (18–45  years) [37]. At the time of this 
investigation samples were only available for 36 adults. 
Samples collected before (Day 0) and on Day 84 after 
vaccination (4  weeks after the last immunization) were 
analysed to assess if vaccination has an effect on the 
development of antibody response to the sexual stages 
of P. falciparum. During the GMZ2 trials, participants 
received three doses of either 30 or 100 μg GMZ2, adju-
vanted with aluminum hydroxide or a control vaccine 
(Verorab) and were followed for 1 year. Further details of 
the studies are published elsewhere [36, 37]. Serum sam-
ples were stored at −80 °C until analysed.
The studies were conducted according to the principles 
of the Declaration of Helsinki and good clinical prac-
tice guidelines. The respective competent ethics com-
mittees: the Comité d’Ethique Régional Indépendant de 
Lambaréné, CERIL and the Gabonese Ministry of Health 
reviewed and approved the studies. A signed informed 
consent was obtained from each participant or parent/
guardian of participant aged less than 18 years. Analysis 
of Ab levels against P. falciparum was part of the respec-
tive study protocols.
Gametocyte culture and purification
Gametocyte culture was initiated from a continuous 
culture of asexual P. falciparum parasites as described 
earlier [39]. Briefly, the asexual cultures were kept at 5% 
haematocrit and less than 2% parasitaemia at 37  °C, 5% 
 CO2 and 5%  O2 with weekly sorbitol synchronization and 
daily change of medium (RPMI 1640 supplemented with 
25 mM HEPES, 28 mM  NaHCO3, 50 μg/mL gentamycin, 
0.5% w/v Albumax II, 2.4 mM l-glutamine, and 0.14 mM 
hypoxanthine); medium of the clinical isolate contained 
in addition 5% human serum. The P. falciparum labora-
tory strain NF54 (Sanaria Inc., Rockville, MD, USA) and 
a laboratory adapted clinical isolate from Lambaréné, 
Gabon where the samples had been collected were used 
for the experiments. The clinical isolate (JH013) was cul-
tivated from a blood sample collected in 2009 from an 
individual with P. falciparum mono-infection and cryo-
preserved at −150  °C in glycerolyte as reported previ-
ously [40].
Gametocyte culture was performed as described ear-
lier [41, 42] with some modifications. Human serum 
(5%) was added to the gametocyte growth media and the 
culture was initiated with a parasitaemia of 0.5 and 9% 
haematocrit and kept at 5%  O2/CO2 at 37  °C with daily 
change of medium without parasite dilution. On Day 
7 the haematocrit was lowered to 4.5% by doubling the 
volume of medium. Beginning with Day 11 the parasites 
were treated with 50  mM N-acetyl-d-glucosamine (MP 
Biomedicals GmbH, Santa Ana, CA, USA) for 4 days to 
eliminate asexual stage parasites.
To enrich stage V gametocytes from approximately 2% 
to more than 90% on Day 15 a density gradient centrifu-
gation (800g for 20  min) on 33% NycoPrep 1.077 cush-
ions (AXIS-SHIELD PoC AS, Oslo, Norway) followed by 
magnetic separation with LD-MACS magnetic columns 
(Miltenyi Biotec, Gladbach, Germany) was performed.
Fluorescence microscopy and flow cytometry‑based IFA
For IFA, gametocyte-infected erythrocytes were analyzed 
in three different ways: live [15], fixed, or fixed and per-
meabilized [43]. For assessment of Ab response to plas-
modial antigens, a P. falciparum culture was used, that 
was enriched for late developmental stages of asexual 
[44] and stage V gametocytes. In brief, for fixation, para-
sites were incubated for 30 min in a mixture of 4% Elec-
tron Microscopy (EM) grade paraformaldehyde (Merck, 
Germany) and 0.0075% EM grade glutaraldehyde (Sigma-
Aldrich, Germany), then washed once with PBS and 
stored at 4  °C until the IFA was performed. Prior to Ab 
staining, a fraction of fixed cells was permeabilized by 
PBS/0.1% Triton-X-100 for 10 min and washed once with 
PBS.
All live, fixed or fixed and permeabilized parasites were 
blocked using PBS/3%BSA for 1 h before the addition of 
test or negative control sera. Following the blocking step, 
evaluation of anti-gametocyte Ab response was done 
using cytometry-based IFA as described earlier [44]. 
Serum samples (in PBS/3% BSA diluted 1/4000 and 1/50, 
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respectively) from adults and children were added and 
incubated for 1 h. Serum dilutions that gave the best dis-
crimination between negative and positive were used. In 
the cohort children are less reactive compared to adults, 
hence lower dilutions were used [45, 46]. After three 
washes with PBS, secondary Ab staining was carried out 
for 1  h with Alexa Fluor 488-labeled rabbit anti-human 
IgG (Life Technologies GmbH, Darmstadt, Germany) at a 
1:3000 dilution and washed three times before the quality 
of the staining was assessed by fluorescence microscopy.
Subsequent acquisition of flow cytometry data was 
done using a FACSCanto II cytometer equipped with the 
FACSDiva software version 6.1.2 (BD Biosciences, San 
Jose, USA). Fluorescence of each event was analysed and 
the result expressed as percentage of positive fluores-
cent cells (PPFC) based on 20,000 erythrocytes (events) 
acquired.
ELISA for measurement of Abs to GMZ2 antigens
For comparison, a subset of previously reported GMZ2-
specific IgG ELISA values (Days 0 and 84) of clinical trial 
participants were used for the current analyses [36, 37]. 
ELISA data were generated using a standardized ELISA 
protocol as described previously [36, 37].
Stool examination for worm infection
During follow up of study participants enrolled in the 
Phase I paediatric clinical trial of GMZ2 [36], stool 
samples were collected. They were freshly examined to 
evaluate the prevalence of soil-transmitted helminths at 
enrolment and on Day 84 as reported earlier [34].
Statistical analysis
GraphPad Prism version 5.0 (GraphPad Software, San 
Diego California) and SPSS version 16 were used for sta-
tistical analysis. Nonparametric tests were used for statis-
tical testing. The significance level was set to a two-sided 
alpha of 0.05 and corrected using the Bonferroni method 
where applicable. Paired samples were tested with the 
Wilcoxon signed-rank test whereas the Mann–Whit-
ney test was applied in case of unpaired data. Spearman 
correlation between Ab responses to whole sexual and 
asexual stage (including recombinant GMZ2) antigens 
were calculated and presented with 95% confidence 
intervals [47]. A sample was declared sero-negative by 
cytometric IFA if the percentage gated cells positive for a 
given marker was within three standard deviations above 
the mean of the negative controls (serum samples from 
malaria naïve individuals).
Results
Recognition of gametocyte antigens by Abs is enhanced 
by fixation and permeabilization
The level and prevalence of Ab response to P. falciparum 
mature gametocytes was evaluated in sera from adults 
(n = 36) and children (n = 30) from the two GMZ2 tri-
als (Table 1) using live, fixed or fixed and permeabilized 
NF54 P. falciparum mature gametocyte infected eryth-
rocytes. As expected, the level of antigen recognition by 
Abs was significantly higher after fixation and permea-
bilization of NF54 P. falciparum gametocyte-infected 
erythrocytes, two-fold and four-fold change, respectively 
(Fig. 1). Apparently, immune recognition of the parasite 
includes antigens not expressed on the surface of eryth-
rocytes (Fig. 2a, b). However, these intracellular antigens 
could also be shared by the asexual and sexual antigens of 
the parasite. Therefore, for all subsequent measurements, 
Table 1 Study name, background characteristics, grouping, hematological profiles and time of data collection of samples 
used within the study
Study identifier 
(population)
Sampling period 
(month/year)
No. of partici‑
pants
Median age 
in years (range)
Mean hemoglobin 
(g/dL)
Vaccine alloca‑
tion
Samples 
time points
GMZ2_3_08
(Children) [36]
09/2008–10/2009 30 3.5 (1–5) 10.5
10.5
10.3
GMZ2 100 µg
GMZ2 30 µg
Rabies
Days 0 and 84
GMZ2_2_07
(Adults) [37]
07/2007–08/2008 32 26.3 (18–45) 13.8
14.1
GMZ2 100 µg
Rabies
Days 0 and 84
Fig. 1 Antibody response to in vitro differentiated live, fixed or 
permeabilized Plasmodium falciparum gametocytes. The figure shows 
the flow cytometric data obtained using live, fixed or permeabi-
lized gametocyte-infected erythrocytes. Dots represent percentage 
positive cells (erythrocytes positive for AlexaFluor-488), one dot per 
tested sample. Gates were set against controls, which are serum from 
malaria naïve individuals. NF non fixed, NP non permeabilized, F fixed, 
P permeabilized. The Y-axis shows percentage of erythrocytes positive 
for the used marker (Alexa.Fluor-488)
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non-fixed and non-permeabilized gametocyte-infected 
erythrocytes were used.
Anti‑gametocyte Ab responses of malaria‑exposed 
individuals in different P. falciparum parasite strains
The anti-gametocyte Ab-binding patterns of one clini-
cal isolate (JH013) and NF54 were compared to identify 
the strain that is best recognized by participants’ Abs 
[37]. There was no significant difference between the 
two strains in the recognition of gametocytes by serum 
antibodies from adults and children of the studies and, 
therefore, further experiments were done only with the 
P. falciparum laboratory strain NF54. The Ab response 
to mature gametocytes was higher in adults compared 
to children (Fig.  3), as well as the seroprevalence of 
anti-gametocyte Ab response (77% in adults and 57% in 
children).
Asexual and sexual stage anti‑malarial immune response 
in GMZ2 vaccinated adults and children
The effect of GMZ2 vaccination on the development of 
anti-gametocyte immune response in adults and children 
was assessed. It was hypothesized that immune responses 
generated by the GMZ2 vaccine may divert the immune 
response towards the vaccine or lead to a lower gameto-
cyte density, despite its relatively low efficacy (11–14%) 
Fig. 2 Microscopic IFA of antibody response to P. falciparum gametocytes. The figures show an example picture of AlexaFluor-488 stained parasites 
by fluorescence microscopy before (a) and after (b) permeabilization
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in children between 1 and 5  years [38]. Interestingly, 
the anti-gametocyte Ab response in GMZ2 vaccinated 
adult individuals was lower on Day 84 after vaccination 
compared to baseline (Day 0) (Fig.  4a). In children, the 
anti-gametocyte Ab response was not different after vac-
cination in both, the GMZ2 and rabies vaccinated control 
group (Fig. 4b).
Since sexual stage immunity may be developed inde-
pendently from asexual-stage immunity [13, 15], possible 
associations were tested between sexual stage immune 
response (anti-gametocyte Abs) to the asexual stage 
immunity (Abs against asexual blood stages) and Ab 
responses to the GMZ2 vaccine antigen in the two vacci-
nated groups. For this analysis, our previously published 
data on anti-plasmodial (against whole asexual stage 
antigens) [44] and anti-GMZ2 [36, 37] Abs were used 
to assess correlations with anti-gametocyte Abs. There 
was a positive correlation on Day 0 before vaccination 
between the sexual and asexual Ab responses in the semi-
immune population (Table 2). No correlation was found 
in data from children. The Ab response to GMZ2 was not 
associated with sexual Ab response neither in adults nor 
in children (Table 2).
Effect of helminth infection on development 
of anti‑gametocyte immunity
The anti-plasmodial immune response is modulated 
by co-infection of P. falciparum with other infectious 
agents including helminths [48–50]. Previously an effect 
of intestinal helminths on anti-GMZ2 responses in 20 
GMZ2 vaccinated children was found [34] and, there-
fore, also in this study the effect of intestinal parasites co-
infection on the modulation of anti-gametocyte immune 
responses in children was assessed. Parasitological data 
of all 30 children included in the GMZ2 Phase Ib trial 
[36] were used to explore the modulation of anti-game-
tocyte immune response by helminths. Overall, five dif-
ferent helminths were recorded. Trichuris trichiura and 
Ascaris lumbricoides were present in a relative high pro-
portion on enrolment (14/30; 47% and 8/30; 27%) and on 
Day 84 (15/30; 50% and 11/30; 37%), respectively. There 
was also a low rate of infections (<7%) by Strongyloides, 
Fig. 3 Baseline levels of antibody response to gametocytes of P. 
falciparum in semi-immune adults and malaria exposed children. 
Antibody response (percentage of positive cells) against in vitro 
developed matured gametocytes (P. falciparum NF54 strain) of the 
serum samples of the different trials conducted in Gabon (GMZ2 
children on Day 0 [36] and GMZ2 adults on Day 0 [37]) at baseline. 
Median, 25th and 75th percentiles, and minimum and maximum 
ranges are indicated
Fig. 4 Effect of GMZ2 vaccination on the development of antibody response to mature P. falciparum gametocytes. a, b Show the antibody 
response in semi-immune adults and malaria-exposed children, respectively. In adults, 73.3% (11/15) show a decrease of Ab response after vac-
cination while 20% (3/15) show an increase and one person has shown no change (6.7%). D0 Day 0, D84 Day 84, GMZ2 100 µg or GMZ2 30 µg: 
participants who received 100 or 30 µg of GMZ2 vaccine, respectively. Rabies: participants who received the control rabies vaccine
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Schistosoma, and Ancylostoma. Interestingly, children 
infected with Ascaris lumbricoides had significantly 
higher anti-gametocyte Ab response compared to unin-
fected children when using live non-permeabilized 
gametocytes (Fig.  5a). When the assay was done using 
fixed and permeabilized parasites, a significantly lower 
Ab response was observed in Trichuris trichiura-infected 
children (Fig. 5b).
Discussion
Understanding the development of Ab responses to 
sexual stages of P. falciparum in malaria-exposed popu-
lations is important for understanding transmission 
patterns and the design and development of TBVs. In this 
study in a highly malaria endemic area, adults showed 
higher Ab responses to sexual stage antigens than chil-
dren. The effect of age on anti-gametocyte Ab production 
and transmission reducing activity has been addressed 
in several studies and resulted in contradictory results. 
Some have shown an increase in antibody response to 
fixed whole parasites [51] and to Pfs48/45 and Pfs230 
with age [46], others a decline in transmission reducing 
activity of sera with age [27]. The difference may be due to 
the varying age ranges, different epidemiological settings 
and inconsistent assays for anti-gametocyte Ab meas-
urements between the studies. Since effective humoral 
Table 2 Spearman correlation of  the antibody response to  sexual stage antigens with  asexual stage antigens and  the 
GMZ2 vaccine antigen of P. falciparum in adults/children from Gabon
C-IFA Cytometric immunofluorescence assay, ELISA Enzyme-linked immunosorbent assay, PPFC percent positive fluorescent cells, CI Confidence interval
Significant p value is indicated as follows: * P < 0.05
a  D0 Values represent both GMZ2 and Rabies groups together. D0 Day 0, D84 Day 84
Study participants and vaccination Antibody against whole asexual stage anti‑
gens by C‑IFA (Mean PPFC)
Antibody against GMZ2 
by ELISA (Mean Ab titers)
Rho (95% CI) Rho (95% CI)
Antibody against stage V gametocytes by C-IFA (Mean PPFC)
Adults
 D0a 0.39 (0.03, 0.66)* 0.17 (−0.18, 0.48)
 D84 (GMZ2) 0.41 (−0.17, 0.78) 0.44 (−0.13, 0.80)
 D84 (Rabies) 0.40 (−0.21, 0.79) 0.54 (−0.03, 0.85)
Children
 D0a 0.16 (−0.24, 0.51) 0.28 (−0.11, 0.60)
 D84 (GMZ2, 30 µg dose) 0.02 (−0.62, 0.64) −0.10 (−0.69, 0.57)
 D84 (GMZ2, 100 µg dose) 0.06 (−0.59, 0.67) 0.22 (−0.48, 0.75)
 D84 (Rabies) −0.27 (−0.77, 0.44) 0.22 (−0.48, 0.75)
Fig. 5 Antibody response to P. falciparum mature gametocytes in children from Gabon infected with intestinal parasites. The x-axis shows helminth 
infection status on Day 0 before vaccination in children, N = 30. a, b show antibody recognition of live and permeabilized gametocyte infected 
erythrocytes, respectively. Y-axis shows percentage of erythrocytes positive for AlexaFluor-488. PPFC  % positive fluorescent cells, IQR Interquartile 
range. Median and IQR are indicated
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immunity to intraerythrocytic gametocytes requires pro-
longed exposure to the parasite [52], the epidemiological 
setting shall play an important role and the interpretation 
of divergent results needs to account for that.
The anti-gametocyte seropositivity rate was 77% in 
adults and 57% in children. Similar seropositivity rates 
have been recorded earlier, more than 50% in Ghana-
ian children with asymptomatic infection [53] and 34% 
in Gambian children with uncomplicated malaria and 
gametocytaemia [15]. In another cohort of Gambian 
children, who were gametocytaemic, an Ab response 
was detected in all participants [51]. This response 
might have been so high, as they fixed gametocytes with 
acetone that simultaneously permeabilizes the cell [54]. 
The same study reported a lower (42%) sero-prevalence 
when live gametes were used. Unfortunately, gametocyte 
carriage rates were not recorded in our studies. Due to 
different methodologies, direct comparison to the pre-
viously reported results is not possible. Of note, game-
tocyte prevalence is not always associated to antibody 
response to gametocytes [55] and transmission capacity 
[56, 57].
The effect of anti-GMZ2 Ab and Ab responses to whole 
asexual stage antigens and the effect of GMZ2 vaccina-
tion on the development of sexual-stage immunity was 
evaluated. The result showed a significant but weak posi-
tive correlation between Ab response to gametocyte anti-
gens and whole asexual stage antigens, but not to GMZ2 
antigen in adults, showing that exposure is correlated to 
Ab response to gametocytes in the investigated popula-
tion. The level of sexual Ab response was significantly 
reduced after vaccination in GMZ2 vaccinated adults, 
but this difference was not seen in the rabies control 
group. An effective asexual malaria vaccine should lead 
to a reduced asexual parasite load and, therefore, reduced 
gametocyte production. The recently reported results of 
the GMZ2 vaccine shows 11–14% efficacy in children 
[38], therefore, the expected effect on gametocytes would 
be rather low. There is no evidence for the expression 
of either of the GMZ2 component proteins (MSP3 and 
GLURP) on the surface of gametocyte infected erythro-
cytes even though it was previously reported that GLURP 
is expressed in different stages of the parasite life cycle 
including the pre-erythrocytic stage [58]. The results 
show no boosting of the anti-gametocyte Ab response, 
supporting the data that none of the components is pre-
sent at the sexual stage.
In children, there was no correlation between the Ab 
response to gametocyte antigens and GMZ2 (and other 
asexual antigens). The difference of the correlation results 
between adults and children might be due to the very 
low level of anti-gametocyte immune response in chil-
dren complicating to see differences between groups. 
Additionally, Ab response to matured gametocytes did 
not change in children following vaccination with GMZ2 
or the rabies control vaccine. Unfortunately our analysis 
has been underpowered to detect subtle differences in 
the study populations. Our result shall be confirmed with 
a bigger sample size.
As expected, antigen recognition by immune sera was 
significantly enhanced after fixation and permeabiliza-
tion of gametocyte-infected erythrocytes as reported 
earlier [51]. This effect may be partly due to intracellu-
lar targets of transmission-blocking Abs [52] that are not 
exposed on the infected erythrocyte surface. However, 
the response measured after fixation and permeabiliza-
tion of cells might not be gametocyte specific, but rep-
resent a response to the cocktail of internal asexual and 
sexual stage proteins [59]. Therefore, non-fixed and non-
permeabilized gametocyte-infected erythrocytes were 
used to analyse the effect of age, vaccination, coinfection, 
and parasite strain variation on Ab responses to gameto-
cytes. The natural Ab response to gametocyte antigens 
might inhibit gametocyte development and thereby inter-
rupt the transmission of the parasite as shown in vitro by 
co-cultivation of early gametocytes with plasma from 
malaria patients [5]. In addition, Abs may also act follow-
ing exflagellation in the mosquito midgut [60]. To get a 
deeper insight, characterization of naturally acquired 
transmission blocking Abs might improve the portfolio 
of TBVs.
Recognition of P. falciparum gametocytes of the labora-
tory strain NF54 and a clinical isolate by serum antibod-
ies of semi-immune adults was assessed. Both lab strain 
and clinical isolate have been detected by the serum anti-
bodies and no significant difference in the level of Ab 
recognition of the two strains could be seen. This was 
unexpected as the clinical isolate was collected from the 
area where the study participants were recruited. How-
ever, similar to the finding presented here, it has been 
shown earlier by Dinko et al. that the plasma antibodies 
from Ghanian participants recognizing the laboratory 
strain 3D7 and a clinical isolate from Kenia [55].
The immune response to malaria is modulated by 
co-infection with other infectious agents [33]. There 
were lower Ab responses in Trichuris trichiura infected 
children when the assay was done with permeabilized 
gametocytes. However this might not represent the 
suppression of the immune response to gametocytes 
but rather the response to the asexual or both stages 
of the parasite. This corroborates earlier findings in the 
same population, which showed that Trichuris trichiura 
infection is associated with 3.4-fold reduced Ab lev-
els to the blood-stage asexual GMZ2 vaccine antigen 
while the response was increased in Ascaris lumbri-
coides-infected participants [34]. However, the effect 
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of Trichuris trichiura infection could not be seen in the 
assay using non-permeabilized gametocyte-infected 
erythrocytes. In line with this, a cross-sectional study 
has reported a significant reduction of gametocyte spe-
cific (Pfs48/45) antibody titers in individuals infected 
with Schistosoma haematobium, though this effect is 
not seen when comparing another gametocyte specific 
antigen (Pfs230) [61].
The response to any gamete-specific antigens was not 
measured and therefore activation of non-fixed gameto-
cytes cannot be ruled out. Mature gametocytes should 
be handled with care and a drop in temperature could 
provoke exflagellation. Therefore, the small fraction of 
recognized erythrocytes with gametocytes could also be 
a small fraction that was accidentally activated. However, 
we tried to ensure that non-fixed and non-permeabilized 
erythrocytes in the assay were intact and controlled for 
exflagellation by microscopy. Therefore, the measured 
response most probably represents largely the antibody 
response to antigens displayed on the surface of gameto-
cyte-infected erythrocytes. Another explanation for the 
low response could be that only a fraction of gametocytes 
transport proteins to the outside and express surface pro-
teins on the surface of erythrocytes. A reduced transport 
of proteins to the erythrocyte surface is known for asex-
ual parasites of laboratory strains in long-term culture. 
To check this, the prevalence of positive cells was tested 
also for one clinical isolate (JH013), but did not find a dif-
ference in the percentage of recognized cells when com-
pared to NF54.
Infection with Ascaris lumbricoides resulted in an 
increased anti-gametocyte immune response compared 
to the uninfected participants. This was surprising but 
similar effects on the anti-malarial immune response 
have been observed earlier [34]. However, due to the 
relatively small sample size and exploratory nature of the 
experiment, confirmatory studies will be required. There-
fore, monitoring of anti-gametocyte responses should 
be done in further larger studies. In addition, it would 
be interesting to validate the immuno-modulatory effect 
of co-infections on the development of asexual and sex-
ual stage immune responses and the transmissibility of 
malaria in other co-endemic areas.
Conclusions
The level of Ab responses to mature gametocytes can be 
measured using flow cytometry. Adults show higher Ab 
responses when compared to children. Anti-gametocyte 
Ab responses are enhanced following permeabilization 
but may include responses to asexual antigens. Helminth 
infections and anti-malarial interventions modulate the 
humoral immune response to asexual and sexual blood 
stage P. falciparum parasitaemia. This may have a signifi-
cant impact on malaria control strategies with the aim to 
reduce transmission of malaria.
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Effect of Fluorescent Dyes on In Vitro-Differentiated, Late-Stage
Plasmodium falciparum Gametocytes
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Plasmodium falciparum gametocytes are not associated with clinical symptoms, but they are responsible for transmitting the
pathogen to mosquitoes. Therefore, gametocytocidal interventions are important for malaria control and resistance contain-
ment. Currently available drugs and vaccines are not well suited for that purpose. Several dyes have potent antimicrobial activ-
ity, but their use against gametocytes has not been investigated systematically. The gametocytocidal activity of nine synthetic
dyes and four control compounds was tested against stage V gametocytes of the laboratory strain 3D7 and three clinical isolates
of P. falciparumwith a bioluminescence assay. Five of the fluorescent dyes had submicromolar 50% inhibitory concentration
(IC50) values against mature gametocytes. Three mitochondrial dyes, MitoRed, dihexyloxacarbocyanine iodide (DiOC6), and
rhodamine B, were highly active (IC50s< 200 nM). MitoRed showed the highest activity against gametocytes, with IC50s of 70
nM against 3D7 and 120 to 210 nM against clinical isolates. All compounds were more active against the laboratory strain 3D7
than against clinical isolates. In particular, the endoperoxides artesunate and dihydroartemisinin showed a 10-fold higher activ-
ity against 3D7 than against clinical isolates. In contrast to all clinically used antimalarials, several fluorescent dyes had surpris-
ingly high in vitro activity against late-stage gametocytes. Since they also act against asexual blood stages, they shall be consid-
ered starting points for the development of new antimalarial lead compounds.
Malaria leads to approximately 1 million deaths annually andremains a highly relevant public health problem in tropical
and subtropical regions (1). Plasmodium falciparum, the most vir-
ulent species, is responsible for most of the morbidity from ma-
laria and accounts for almost all mortality from malaria in sub-
Saharan Africa. Gametocytes are the stage responsible for
transmission of the parasite from the human host to the mosquito.
During the asexual blood stage, a small fraction of parasites dif-
ferentiates into gametocytes. In P. falciparum, differentiation
from sequestered immature stages (stages I to IV) to the free cir-
culating mature stage (stage V) occurs within 8 to 14 days in in-
ternal organs, mainly bone marrow (2–4). When a mosquito takes
a blood meal, it ingests stage V male and female gametocytes,
which can further develop in the mosquito. In the mosquito gut,
gametocytes develop into gametes that join to become a zygote,
which then matures into the ookinete, followed by the oocyst
stage. This stage gives rise to sporozoites, which are released from
the oocyst and migrate to the salivary glands of the mosquito,
where they can be transmitted during a subsequent blood meal.
Even though gametocytes are essential for the spread of ma-
laria, transmission-blocking agents have not been a priority in the
search for antimalarial drugs for a long time. This has recently
changed with the ambition to eradicate malaria (5). The develop-
ment of a new generation of transmission-blocking tools and ther-
apies is a top priority of the Malaria Eradication Research Agenda
(malERA) since they are believed to be essential for the elimina-
tion and subsequent eradication of malaria (6, 7).
Most current antimalarial drugs show, at most, only modest
activity against early gametocytes but have either negligible or no
effect on stage V gametocytes, although all are active against the
asexual blood-stage parasites (8–10) and some inhibit the growth
of preerythrocytic stages. Primaquine, an 8-aminoquinoline, is
the only licensed drug that has proven gametocytocidal activity in
vivo. Its use is limited due to the risk of hemolysis in people with
glucose-6-phosphate dehydrogenase (G6PD) deficiency, a com-
mon trait in areas where malaria is endemic. In addition, prima-
quine is a prodrug that requires activation by cytochrome P450
2D6 (CYP2D6), which is polymorphic and can lead to treatment
failures in poor and intermediate metabolizers (11). Other drugs
with activity against gametocytes are bulaquine, a compound
newly registered in India (12), and tafenoquine, which has been in
late-phase clinical development for more than a decade (13). Both
drugs are 8-aminoquinolines and are likely to share safety and
efficacy problems with primaquine in G6PD-deficient individuals
and poor metabolizers of CYP2D6, respectively (14). Dihydroar-
temisinin (DHA), the active metabolite of all artemisinin deri-
vates, has been reported to be active against stage I to III gameto-
cytes (15, 16), but it is uncertain whether DHA has clinically
relevant activity against late-stage gametocytes (8). Evidence
available from clinical studies shows that transmission is only par-
tially blocked following treatment with artemisinin-based combi-
nation therapies (17, 18), the current mainstay of antimalarial
therapy in areas where malaria is endemic.
In conclusion, no licensed drug with a satisfactory profile that
can be used to control the transmission of P. falciparum is avail-
able. Some synthetic dyes have potent antimicrobial activity and
have been successfully used as antimalarials since the late 19th
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century, when Guttmann and Ehrlich used the thiazine dye meth-
ylene blue for the treatment of malaria (19). Since then, several
other dyes were tested for their antiplasmodial activity (20, 21).
We revived this idea in a previous study by testing a panel of
synthetic dyes for their in vitro activity against asexual stages and
identified several compounds with high levels of in vitro activity
(22). Methylene blue is known to show gametocytocidal activity
(15, 23–25); therefore, we evaluated the activity of eight other
antimalarial dyes against P. falciparum stage V gametocytes de-
rived from the laboratory strain 3D7 and three clinical isolates
from Lambaréné, Gabon, with an established bioluminescence
assay (8).
MATERIALS AND METHODS
Cultivation of asexual parasites. P. falciparum strain 3D7 (Malaria Re-
search and Reference Reagent Resource, ATCC, Manassas, VA, USA) and
clinical isolates obtained from Lambaréné, Gabon, were kept in continu-
ous culture as described earlier (26). Clinical isolates were from a study
reported previously (27). Blood was sampled directly from patients with
P. falciparum monoinfection and cryopreserved in glycerolyte at150°C
until culture for the experiment was initiated. The cultures of both 3D7
and clinical isolates were kept at 5% hematocrit in complete culture me-
dium (RPMI 1640 supplemented with 25 mM HEPES, 28 mM NaHCO3,
50 g/ml gentamicin, 0.5% [wt/vol] lipid-rich bovine serum albumin
[Albumax II], 2.4 mM L-glutamine, and 0.14 mM hypoxanthine at 5%
CO2 and 5% O2). For clinical isolates, 5% human serum was added to the
complete culture medium. Medium was replaced every 24 h.
Gametocyte culture and purification. Gametocyte culture was per-
formed as described previously (8), with some modifications. Cultures
were started from asexual parasites and kept in continuous culture with
sorbitol synchronization twice weekly (28). Culture medium for gameto-
cytes always contained 5% human serum. Initially, the culture was ad-
justed to 9% hematocrit and 0.5% parasitemia and kept at 5% O2 and 5%
CO2 at 37°C with a daily change of medium without parasite dilution for
2 weeks. In the second week, the volume of medium was doubled and
cultures were treated with 50 mM N-acetyl-D-glucosamine (MP Biomedi-
cals GmbH, Santa Ana, CA, USA) for 4 days, beginning 11 days after
initiation to remove asexual parasites. To enrich stage V gametocytes from
approximately 2% to over 90%, a two-step purification was performed on
day 15 using a NycoPrep 1.077 cushion density gradient (Axis-Shield PoC
AS, Oslo, Norway), followed by magnetic separation with LD-MACS
magnetic columns (Miltenyi Biotec, Gladbach, Germany) to remove the
remaining erythrocytes. Purification was done at 37°C to keep the game-
tocytes viable and avoid exflagellation during the procedure.
Viability of mature gametocytes after separation. The viability of
gametocytes after purification was assessed by microscopy (Fig. 1) and the
capacity of male gametocytes to exflagellate in exflagellation medium
(complete culture medium with 5% human serum and 100 M
xanthurenic acid) for 20 min at room temperature, as described earlier
(25, 29).
Compounds. We selected eight fluorescent dyes (see the structures in
Fig. 2) on the basis of their activity against asexual parasite stages evalu-
ated previously (22), in addition to methylene blue and control com-
pounds. The panel of fluorescent dyes consisted of three nucleic acid dyes,
Hoechst 33342 (CAS number 23491-52-3), acridine orange (CAS number
65-61-2), and SYTO 9 (SYTO 9 green fluorescent nucleic acid stain; the
structure is proprietary), and five mitochondrial dyes, MitoRed (Mito-
Tracker Red CMXRos; CAS number 167095-09-2), MitoGreen (Mito-
Tracker Green FM; CAS number 201860-17-5), dihexyloxacarbocyanine
iodide (DiOC6; CAS number 53213-82-4), rhodamine 123 (molecular
weight [MW], 380.83; CAS number 62669-70-9), and rhodamine B (hexyl
ester perchlorate; MW, 627.17; CAS number 877933-92-1). We compared
the activities of these dyes to those of methylene blue (MW, 319.86; CAS
number 61-73-4), epoxomicin (MW, 554.7; CAS number 134381-21-8),
DHA (MW, 284.35; CAS number 71939-50-9), artesunate (MW, 384.4;
CAS number 88495-63-0), and primaquine (primaquine phosphate;
MW, 455.33; CAS number 63-45-6). Methylene blue was obtained from
AppliChem. All other dyes were from Invitrogen. Epoxomicin and DHA
were obtained from Calbiochem and Shinpoong, respectively. Artesunate
and primaquine were from Santa Cruz Biotechnology.
Methylene blue and acridine orange were dissolved in water, while all
other tested dyes were dissolved in dimethyl sulfoxide (DMSO). Further
dilutions were done with complete culture medium. Final DMSO concen-
trations were less than 0.5%, a concentration that does not interfere with
gametocyte viability.
Epoxomicin was used as a positive control, as it is a potent inhibitor of
all clinically relevant parasite stages, including gametocytes, in vitro.
ATP-based bioluminescence assay.We used a bioluminescence assay
based on the luciferin-luciferase ATP-dependent reaction to assess the
activity of the different compounds against mature gametocytes.
The assay was performed as previously described with some modifi-
cations (8, 30). In brief, compounds were 3-fold serially diluted in a 96-
well plate. After purification, gametocytes were counted microscopically
using an improved Neubauer cell-counting chamber, and 5 104 purified
stage V gametocytes were added to each well in a final volume of 100l. In
order to validate the test protocol and determine the linear relationship
between the ATP content and the number of gametocytes in culture me-
dium, we generated a standard curve using a 2-fold serial dilution starting
FIG 1 Giemsa-stained mature gametocyte culture on day 15 before (A) and after (B) purification.
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with 5 104 purified mature gametocytes. On every plate, a serial dilution
of viable stage V gametocytes was added as a control.
ATP measurements were done using equal volumes (50 l) of game-
tocyte culture and BacTiterGlo reagent (Promega, Mannheim, Germany)
in white opaque-walled 96-well plates, which were incubated at room
temperature in the dark for 5 min to allow cell lysis and stabilization of the
luminescent signal. Subsequently, the luminescence signal was recorded
with a luminometer (LUMO; Anthos Mikrosysteme, Krefeld, Germany).
Stage V gametocytes were exposed to serial dilutions of the test com-
pounds for 24 h or 48 h to assess the effect of the incubation time on the
activity. Experiments using 3D7 and a 48-h incubation time were per-
formed at least three times independently.
Statistical analysis. We used the drc package (version 2.3.7) of R (ver-
sion 2.15.1) to calculate the inhibitory concentrations of compounds by
nonlinear regression analysis of log concentration-response curves. The
50% inhibitory concentrations (IC50s) were determined for each com-
pound. If more than two experiments were performed, the mean and
standard deviation are given. The coefficient of determination (R2) was
calculated to assess correlations.
Ethical approval. We used three clinical isolates described in a previ-
ous study (27). The study was approved by the ethics committee of the
International Foundation for the Albert Schweitzer Hospital in Lam-
baréné and followed the principles of the Declaration of Helsinki (6th
revision). The participating children and legal representatives gave assent
and informed consent, respectively.
RESULTS
Viability of mature gametocytes and validation of lumines-
cence. As a first step, we evaluated the viability of gametocytes
after purification and validated the ATP readout. Gametocytes
appeared noncompromised after purification with intact cyto-
plasm (Fig. 1), male gametocytes showed exflagellation, and stage
V gametocytes consistently remained viable for approximately 3
weeks. ATP levels and the number of gametocytes in the assay
correlated closely (R2 0.99).
Activity of fluorescent dyes against mature stage V gameto-
cytes. Five of the eight fluorescent dyes in our assay showed IC50s
below 1 M (Table 1). Among the dyes tested, the three mito-
chondrial dyes, MitoRed, DiOC6, and rhodamine B, showed the
best activity, with IC50s being below 200 nM, which is even lower
FIG 2 Chemical structures of the tested synthetic dyes. The structure of SYTO 9 is proprietary.
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than the IC50 of the control dye, methylene blue (770 nM). Among
all dyes, MitoRed was the most active compound against labora-
tory strain 3D7 as well as against clinical isolates. The activities of
the different dyes as well as the control drugs were consistently
higher against the laboratory strain 3D7 than against clinical iso-
lates (2- to 10-fold). Particularly, artesunate and DHA had con-
siderably higher IC50s against clinical isolates than against 3D7. As
expected for a prodrug, primaquine did not inhibit gametocytes at
concentrations achievable in vivo. Epoxomicin served as our in-
ternal positive control and was highly active against the 3D7 lab-
oratory strain and clinical isolates. The IC50s of the single com-
pounds against asexual blood stages are given for comparison
(Table 1). All compounds except epoxomicin were less active
against gametocytes than against asexual blood stages.
Activities of compounds after different incubation times (24
h and 48 h) with mature gametocytes. In vitro gametocyte assays
are poorly standardized and use different incubation times to test
gametocytocidal compounds (8, 30). To assess the influence of the
incubation time on the antiparasitic activity, we incubated fluo-
rescent dyes and standard antimalarial drugs for either 24 h or 48
h with stage V gametocytes of 3D7 parasites and clinical isolates.
For most compounds the incubation time had no significant effect
(Table 2). However, MitoRed was 3-fold more active when used
over 48 h than when used over 24 h. This effect was even more
pronounced for epoxomicin and artesunate incubations, with a
10-fold increase in activity when parasites were exposed for 48 h.
DISCUSSION
The primary aim of antimalarial treatment is to remove asexual
blood-stage parasites in order to cure the disease and prevent or
treat severe forms of malaria. In contrast, late-stage gametocytes
do not cause significant harm to the infected individual and ap-
pear in the circulation after a lag period due to sequestration. Most
of the current antimalarials act against asexual blood stages but
have no significant effect on sexual stages, which remain in the
circulation for extended periods after treatment and could there-
fore be transmitted (31, 32). To achieve sustained malaria control
and contain resistance development, an efficient gametocytocidal
drug is fundamental. We identified five synthetic dyes with good
gametocytocidal activity. These five dyes, particularly the three
mitochondrial dyes MitoRed, DiOC6, and rhodamine B, were
more active than methylene blue, a drug with known gametocy-
tocidal activity (15, 23–25). The cytotoxic concentration of the
mitochondrial dyes was higher than 2.5 M when evaluated
against HeLa cells in our previous study (22). MitoRed was the
most active compound against gametocytes. Interestingly, we had
previously selected it as a promising candidate for development as
an antimalarial due to its high activity against asexual blood-stage
parasites and its favorable selectivity index when tested against
HeLa cells. It belongs to the rhodamine dyes. Some of its deriva-
tives are used in the cosmetic industry, where toxicity has been
more extensively studied (33, 34). However, no further toxicity
data on MitoRed are available. The results from the current game-
tocyte assay underline the interesting properties of mitochondrial
dyes as starting points for new antimalarials, and further toxicity
studies of the most promising compounds should be performed.
Interestingly, all compounds except epoxomicin showed higher
activity against asexual blood stages than against gametocytes.
This is likely due to the less active metabolism during the late
gametocyte stage. Dyes selectively target certain organelles in the
TABLE 1 In vitro activities of standard antimalarial drugs and dyes against stage V gametocytes of the P. falciparum 3D7 laboratory strain and
clinical isolates after 48 h of incubationa
Compound or dye
Mean IC50 SD (M)
3D7 gametocytes
Clinical isolates (gametocytes)
3D7 asexual
blood stagesIsolate 1 Isolate 2 Isolate 3
Standard compounds
Epoxomicin 0.0016 0.0007 0.0021 0.0024 0.0015 0.005
DHA 0.20 0.07 2.81 2.66 1.80 0.002
Artesunate 0.38 0.12 4.39 0.99 2.91 0.001
Primaquine 20.05 5.67 4.88 7.11 10.55
Methylene blue 0.77 0.68 1.05 1.49 1.05 0.008b
Dyes with IC50s of300 nM for
3D7 gametocytes
MitoRed 0.07 0.04 0.21 0.18 0.12 0.008b
DiOC6 0.14 0.03 0.11 0.72 0.58 0.011b
Rhodamine B 0.18 0.08 0.23 0.99 0.34 0.026b
Hoechst 33342 0.23 0.06 0.25 0.31 0.44 0.007b
SYTO 9 0.26 0.07 1.34 1.13 1.24 0.021b
Dyes with IC50s of1 M for
3D7 gametocytes
MitoGreen 1.02 0.23 1.66 1.24 1.45 0.116b
Acridine orange 3.04 1.07 36.56 2.63 0.466b
Rhodamine 123 7.13 2.97 13.83 10.39 0.388b
a The activities of the evaluated compounds against mature gametocytes of 3D7 and three different clinical isolates of P. falciparum were measured after 48 h of incubation in
serum-supplemented medium. Results for 3D7 gametocytes are the means of three independent experiments.
b For comparison, the activity of dyes against asexual blood stages evaluated by a histidine-rich protein 2 enzyme-linked immunosorbent assay is given (results are from Joanny et
al. [22]). The activities of epoxomicin, artesunate, and DHA were evaluated with the same method in our laboratory.
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organism, presumably inhibiting the targeted organelle. Interest-
ingly, atovaquone, a potent inhibitor of the cytochrome bc1 com-
plex of the mitochondrion, does not affect gametocyte develop-
ment (8). Nevertheless, mitochondrial dyes are highly active,
which is most likely because they do not share the same mecha-
nism of action.
In addition to P. falciparum 3D7 gametocytes, we used three
clinical isolates from Lambaréné, Gabon, an area of high drug
pressure and widespread chloroquine and folate inhibitor resis-
tance (35, 36). Gametocytes derived from the laboratory strain
3D7 seemed to be more sensitive to most compounds than the
tested clinical isolates. This finding has important implications for
larger screening programs, since hits achieved in laboratory iso-
lates should be considered to be validated in clinical isolates. Pri-
maquine presented one exception to this rule because it is more
active against clinical isolates than against 3D7. However, the in
vitro activity is likely not a good surrogate for the relevant activity
of primaquine in vivo, as it has to be metabolized by CYP2D6 (37,
38) and monoamine oxidase A (38) to be active. Therefore, pri-
maquine shows rather unspecific activity in vitro and can be used
only as a comparator between assays, showing that our results are
in line with results obtained by others (8, 30, 39).
The difference in activities between clinical isolates and 3D7
was particularly high for artemisinin derivatives. Whether or not
this is due to drug pressure may only be hypothesized. Artemisinin
combination therapy has been the recommended first-line ther-
apy since 2003 in Gabon (40). Since then, local parasite popula-
tions may have adapted to the presence of artemisinin derivatives.
It would be very interesting to test parasite isolates obtained before
2003. Unfortunately, such isolates were not available.
A prolonged incubation time influenced the activity of the
drugs. In particular, the most active compounds and artemisinin
derivatives were more active when incubated for 48 h than when
incubated for 24 h. There are two possible explanations for this: (i)
the drug needs a longer time to exert its effect, or (ii) the drug acts
early but the readout detects only late changes in the metabolism
of the gametocytes. Since artemisinin derivatives have a very short
half-life (41), scenario (i) would result in very low in vivo activity,
whereas scenario (ii) is more likely. When we compare the results
to those of our previous assays in which we used medium supple-
mented with Albumax instead of human serum (42), we can also
see an approximately 10-fold increase of the IC50 for artesunate
and DHA for the Albumax-supplemented medium. The in vitro
activity of artemisinin derivatives against late-stage gametocytes is
highly variable and depends on the assay used. Commonly used
methods differ in the numbers of gametocytes, parasite strains,
incubation times, serum supplementation, and readouts used.
These differences result in inhibitory concentrations between 3
nM and 11 M for the same compound (8, 30, 43–45). These
differences demonstrate that better standardization and valida-
tion of assays is required in order to compare results and identify
compounds with promising activities. One method of indepen-
dent validation would be the use of standard membrane feeding
assays. Interestingly, most reports show modest effects (24, 44) or
no effect (46) of artemisinins on oocyst counts following mem-
brane feeding.
In conclusion, fluorescent dyes, especially MitoRed, show high
in vitro gametocytocidal activities and should be considered start-
ing points for the development of new antimalarial compounds
with transmission-blocking potential. In addition to laboratory
strains, gametocytes of clinical isolates should be considered for
the screening of new compounds, as they have a different genetic
background and might show a resistance profile different from
that of laboratory strains.
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Antimalarial Activity of the Myxobacterial Macrolide Chlorotonil A
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Myxobacteria are Gram-negative soil-dwelling bacteria belonging to the phylum Proteobacteria. They are a rich source of prom-
ising compounds for clinical application, such as epothilones for cancer therapy and several new antibiotics. In the course of a
bioactivity screening program of secondary metabolites produced by Sorangium cellulosum strains, the macrolide chlorotonil A
was found to exhibit promising antimalarial activity. Subsequently, we evaluated chlorotonil A against Plasmodium falciparum
laboratory strains and clinical isolates fromGabon. Chlorotonil A was highly active, with a 50% inhibitory concentration be-
tween 4 and 32 nM; additionally, no correlations between the activities of chlorotonil A and artesunate (rho, 0.208) or chloro-
quine (rho,0.046) were observed. Per os treatment of Plasmodium berghei-infected mice with four doses of as little as 36 mg of
chlorotonil A per kg of body weight led to the suppression of parasitemia with no obvious signs of toxicity. Chlorotonil A acts
against all stages of intraerythrocytic parasite development, including ring-stage parasites and stage IV to V gametocytes, and it
requires only a very short exposure to the parasite to exert its antimalarial action. Conclusively, chlorotonil A has an exceptional
and unprecedented profile of action and represents an urgently required novel antimalarial chemical scaffold. Therefore, we pro-
pose it as a lead structure for further development as an antimalarial chemotherapeutic.
Malaria is the most important parasitic disease worldwide,with an estimated 207 million cases causing 627,000 deaths
in 2012 (1). Among Plasmodium spp. causing malaria in humans,
Plasmodium falciparum is responsible for almost all severe and
fatal cases and is the predominant species in sub-Saharan Africa.
Even though the scaling up ofmalaria control programs has led to
a reduction in its incidence and mortality rates (1) and first-gen-
eration vaccines show some efficacy against it (2, 3), chemother-
apy remains the mainstay of treatment for all forms of malaria. A
major threat for chemotherapy is the development of resistance,
since resistant phenotypes have been reported for most registered
antimalarials (4). In sub-Saharan Africa, resistance against the
former first-line drugs chloroquine and sulfadoxine-pyrimeth-
amine is widespread (5), and decreased activity of artemisinin
derivatives is well documented in Southeast Asia (6). The loss of
artemisinin activity is of particular concern, since all current ef-
forts to control malaria are based on this class of compounds (7).
To keep pace with the parasite’s ability to develop resistance, re-
searchers need to make a continuous effort to develop new drugs,
especially in cases of severemalaria, for which only two alternative
treatments (artesunate and quinine) are available (8).
Treatment and pharmacological requirements of drugs to treat
uncomplicated or severe malaria differ fundamentally. Drugs for
uncomplicatedmalaria should be available as an oral formulation,
be easily administered (ideally once), and have a very good safety
profile (e.g., wide therapeutic range; low toxicity, especially in
children and pregnant or lactatingwomen; and fewunwanted side
effects); ideally, they protect the individual for a prolonged time
period and protract resistance development. In contrast, patients
with severe and complicated malaria need fast-acting and usually
parenterally administered drugs, which rapidly reduce the para-
site burden and display activity against all parasite isolates within
a narrow concentration range. Their pharmacokinetic profiles
should allow parenteral administration in critically ill patients
with organ failure. Since children are the most affected group, all
antimalarials must be safe in this age group and must be available
in pediatric formulations (9).
To control malaria on the epidemiological level and prevent
the spread of resistant parasites, antimalarial drugs should act on
gametocytes, the sexual stages of the parasite, to block transmis-
sion to mosquitoes. However, most current antimalarials do not
act against gametocytes, and transmission of the parasite is not
prevented (10). Nevertheless, gametocytocidal activity is highly
desirable for new antimalarials to be used in elimination and erad-
ication programs (11).
In the past, a particularly powerful way to find new chemother-
apeutics against infectious diseases was by characterizing and de-
veloping natural compounds and their derivatizations (12). One
reason for the success rate with natural products may be the long-
lasting interaction of coevolving organisms, resulting in structural
classes optimized for their respective targets. In malaria, most
highly active compounds are plant derived and are thought to
have a role in deterring herbivores (e.g., quinine) or to be potent
herbicides (e.g., artemisinin) (13–16). Besides plants and fungi,
bacteria, including the soil-dwelling myxobacteria (17, 18), are a
rich source of biologically active compounds (19–23). We inves-
tigated the antimalarial properties of a chlorine-containing me-
tabolite, chlorotonil A, whose antiplasmodial activity was primar-
ily identifiedwhen screening a library ofmyxobacterial substances
at the Swiss Tropical and Public Health Institute. Chlorotonil A, a
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tricyclic macrolide produced by Sorangium cellulosum, was first
isolated and described by Gerth et al. (24). The total synthesis of
this substance and its dehalogenated derivative was reported re-
cently (Fig. 1) (25). In our study, we found chlorotonil A to exhibit
potent in vitro and in vivo activity against P. falciparum and P.
berghei, respectively. It acted against all erythrocytic stages of the
parasite, showed a very rapid onset of action, and was active in
vitro against the stages responsible for transmission.
MATERIALS AND METHODS
Parasite culture. P. falciparum strains 3D7 (chloroquine sensitive) and
Dd2 (chloroquine, sulfadoxine, and pyrimethamine resistant)weremain-
tained in continuous culture as previously described (26). In brief, para-
sites were kept in complete culture medium [RPMI 1640, 25 mM
4-(2-hydroxyethyl) piperazine-N=-(4-butanesulfonic acid), 2 mM L-glu-
tamine, 50g/ml gentamicin, and 0.5% (wt/vol) AlbuMax] at 37°C and in
5% CO2 and 5% oxygen at 5% hematocrit with daily changing of the
medium. Synchronization was performed by sorbitol twice a week (27).
Chemicals. Chlorotonil A (molecular weight [MW], 479.44) was iso-
lated as described before (24), and a compound without chlorine atoms
(MW, 410.54) was obtained by dehalogenation (see the structures in Fig.
1). Stock solutions of chlorotonil A and its dehalogenated form were pre-
pared at 2.1 mM and 2.4 mM in tetrahydrofuran (THF). The comparator
drug artesunate (Shin Poong Pharmaceutical Co.) (MW, 384.4) was pre-
pared in 70% ethanol at 15mM, chloroquine diphosphate (Sigma) (MW,
515.86) in double-distilled water at 9.7 mM, and epoxomicin (Sigma)
(MW, 554.7) and dihydroartemisinin (Shin Poong Pharmaceutical Co.)
(MW, 284.35) in dimethyl sulfoxide (DMSO) at 1 mM and 20 mM, re-
spectively. Further dilutions of all drugs were done in complete culture
medium. None of the solvent dilutions used interfered with parasite
growth in the pilot experiments. All results given are in nM.
In vitro drug sensitivity assay of laboratory strains.Drug sensitivity
assays were performed according to standard procedures (28). In brief,
96-well plates were precoatedwith a 2-fold serial dilution of the respective
drug. Ring-stage parasites were diluted to a parasitemia level of 0.05%
with 0 erythrocytes and seeded at a hematocrit level of 1.5% in a total
volume of 225 l per well. After 3 days, the plates were freeze-thawed
twice and analyzed bymeasuring histidine-rich protein 2 (HRP2) with an
enzyme-linked immunosorbent assay (ELISA). To measure the delayed
activity of the drug, we incubated parasites for 6 days (29); on days 2 and
4, themediumwas changed (140l) without replacement of the drug. All
experiments were done in duplicate and repeated at least three times.
In vitro drug sensitivity assay of clinical isolates. We tested the ac-
tivity of chlorotonil A compared to those of standard drugs (artesunate
and chloroquine) against P. falciparum clinical isolates from patients with
uncomplicatedmalaria in Lambaréné,Gabon, between February andMay
2009. The investigations of the in vitro drug sensitivity of the clinical
isolates were approved by the ethics committee of the International Foun-
dation for the Albert Schweitzer Hospital in Lambaréné. Assent and in-
formed consent were obtained from each child and his or her legal repre-
sentative, respectively. A venous blood sample was taken into a lithium
heparin tube and processed within 4 h. The assays were performed as for
lab strains with minor modifications. Plates were precoated with a 3-fold
dilution of each drug, and the parasites were incubated in a candle jar for
3 days at 37°C. Assays were performed only once, directly after the blood
draw. Only samples in which the amount of detected HRP2 at least dou-
bled within the 3 days were included in the analysis.
Stage-specific analysis. Synchronized parasites at the ring, trophozo-
ite, and schizont stages were incubated with the respective drug at a 1.5%
hematocrit level and a parasitemia level between 1% and 4% in a 96-well
plate for a total of 40 h. Samples were taken every 8 h to determine parasite
development microscopically by Giemsa (Sigma)-stained thin blood
smears. Artesunate (20 nM) was used as a positive control for stage-spe-
cific action against rings and trophozoites. For action against the schizont
stage, epoxomicin (500 nM) and artesunate (500 nM) were used as con-
trols. Chlorotonil A was used at a concentration of 40 nM for the deter-
mination of action against the ring and trophozoite stages and also at 500
nM against the schizont stage.
Evaluation of onset of action. Assays were performed as for the in
vitro standard drug sensitivity assay with laboratory strains but with re-
moval of the drug after 1 h. In detail, synchronized ring-stage 3D7 para-
sites were seeded at 0.05% parasitemia level and 1.5% hematocrit level on
precoated 96-well plates (chlorotonil A, artesunate, and chloroquine in a
3-fold serial dilution). After 1 h of incubation, the drugs were removed by
washing with complete medium 3 times. A control plate, for which the
washing step was omitted, was incubated in parallel to compare the re-
sults. Subsequently, incubation of the plates was continued for 3 days as
for the standard assay before the HRP2 ELISA was performed. The 50%
inhibition concentrations (IC50s) of the 1-h pulsed and standard plates of
3 independent experiments were compared. Differences in the IC50s are
presented asmean fold change increase standard deviationwith respect
to the control plates. All experiments were performed in duplicate.
In vivo efficacy. The in vivo antimalarial activity of chlorotonil A was
assessed against that of the rodent malaria strain P. berghei ANKA (pro-
vided by David Walliker, University of Edinburgh, United Kingdom) in
BALB/c and Swiss CD1 mice in the 4-day suppression test (30, 31). In
brief, 4 BALB/cmice and 5 Swiss CD1mice were inoculated intravenously
with 2 107 parasitized erythrocytes (diluted in phosphate-buffered sa-
line [PBS]) obtained from a donor mouse. After being infected, the mice
were treated at 2 h, 24 h, 48 h, and 72 h postinfection with different
amounts of chlorotonil A powder (BALB/c, 36, 68, and 110mg/kg of body
weight [1 control]; Swiss CD1, 3 mice received 100mg/kg [2 controls]) in
100mg of peanut butter (Barney’s Best) or placebo control (peanut butter
only). Peanut butter with or without chlorotonil A was given to each
mouse individually out of a syringe. Thin blood smears from tail blood
were taken daily from days 1 to 5 and stained with 20% Giemsa stain
(Sigma). A minimum of 1,000 erythrocytes per slide was counted micro-
scopically to assess parasitemia. The activity is expressed as percent reduc-
tion of parasitemia in comparison to the control group according to the
following equation: activity  100  (mean parasitemia treated/mean
parasitemia control) 100.
Activity was analyzed on day 4; additionally, we analyzed activity on
day 5, which is recommended for slow-acting drugs (31). The mouse
experiments were approved by the competent authority for animal exper-
iments in Tübingen (no. T1/08) and performed according to German
legislation.
Gametocytocidal activity. The gametocytocidal activity of chloroto-
nil A was evaluated by an ATP bioluminescence assay as described previ-
ously (32). As comparators, artesunate, epoxomicin, and dihydroartemis-
inin were tested. In brief, gametocyte culture was initiated from
synchronized 3D7 parasites with an increased concentration (0.75% [wt/
vol]) of AlbuMax II solution, starting with a 10% hematocrit level and a
0.5% parasitemia level. Culture medium was changed daily without par-
asite dilution throughout the entire process. When the parasitemia level
reached 5%, the volume of the medium was doubled, and the concentra-
tion of AlbuMax II was reduced to 0.5% (wt/vol). Between days 11 and 14,
the cultures were treated with 50 mM N-acetyl-D-glucosamine (MP Bio-
medicals GmbH) to remove the asexual stages, and on day 15, the culture
FIG 1 Chemical structures of chlorotonil A and its dehalogenated form.
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was purified by a NycoPrep 1.077 cushion density gradient and magnetic
column separation in order to remove erythrocytes and enrich the game-
tocyte population.
The compounds were precoated in a 3-fold dilution in 96-well plates
before 50,000 gametocyteswere added to eachwell in a final volumeof 100
l and incubated at 37°C in 5% CO2 and 5% oxygen. After 48 h, ATP
production of the gametocytes was measured by the BacTiterGlo assay
(Promega) according to the manufacturer’s protocol and recorded by a
Victor3 V multilabel reader (PerkinElmer, Inc.). Each experiment was
repeated at least three times.
Statistics. Individual inhibitory concentrations were determined by
nonlinear regression analysis of log-concentration-response curves using
the drc-package v0.9.0 (33) of R v2.3.1 (34). The mean 50% and 90%
inhibition concentrations and standard deviations are presented for each
drug assayed in the laboratory strains. For clinical isolates, the median
50% and 90% inhibition concentrations and their ranges are given. Cor-
relations between the IC50s of clinical isolates of the three different drugs
were calculated with Spearman’s (nonparametric) test for paired samples
in JMP v5.0.1.2 software.
RESULTS
Chlorotonil A acts against laboratory and clinicalP. falciparum
isolates in vitro. Chlorotonil A potently inhibits the growth of
chloroquine-sensitive (3D7) and chloroquine-resistant (Dd2) P.
falciparum parasite strains in vitro (Table 1). As reference com-
pounds, chloroquine and artesunate were analyzed. To assess if
chlorotonil A shows signs of hysteresis (also called delayed-death
phenomenon) similar to those in some other antimalarial antibi-
otics, we performed a 6-day assay covering two intraerythrocytic
cycles of parasite replication. The IC50s obtained in the 6-day assay
were 10.6 4.1 nM (3D7) and 23.5 9.4 nM (Dd2), and the IC90s
were 13.8  6.4 nM (3D7) and 32.4  13 nM (Dd2), indicating
that chlorotonil A acts directly uponfirst contact with the parasite.
The dehalogenated form of chlorotonil A showed no measurable
activity against Dd2 and 3D7, even at the highest concentration
tested (540 nM).
To assess the variability of the activity in clinical isolates of P.
falciparum, we measured the activity of chlorotonil A against par-
asites freshly isolated frompatientswith uncomplicatedmalaria in
Lambaréné, Gabon. Of 28 collected clinical isolates, 25 (chloroto-
nil A and chloroquine) and 26 (artesunate) were successfully
grown in culture and analyzed in the in vitro assay. Chlorotonil A
was active against clinical isolates, with IC50s comparable to those
obtained against laboratory strains; in addition, the determined
IC50s for the clinical isolates showed narrow ranges (Table 2). No
correlations between the activities of chlorotonil A and artesunate
(rho, 0.208; n  25) or chloroquine (rho, 0.046; n  25) were
observed.
Chlorotonil A acts against all blood stages of the parasite.To
investigate the effects of chlorotonil A on the morphology of dif-
ferent stages, we incubated synchronous 3D7 ring, trophozoite,
and schizont stageswith the drug and stained thin blood smears by
Giemsa stain after 8, 24, and 40 h. Chlorotonil A arrested parasite
development in the ring and trophozoite stages. Morphologically,
the parasites looked similar to artesunate-treated parasites, since
their development stopped immediately after contact with the
compound (Fig. 2A and B). When added to schizont-stage para-
sites, higher concentrations (40 nM) were required. Incubation
with 500 nM chlorotonil A led to an arrest in development, which
is comparable to the activity of proteasome inhibitors (e.g., epox-
omicin) that act against the schizont stage (Fig. 2C). Notably,
artesunate added at the same concentration (500 nM) did not
block the egress of parasites; furthermore, erythrocytes newly in-
fected by merozoites were found (Fig. 2C, notice the presence of
ring-stage parasites after 8 h). The chlorotonil A-induced arrest in
the schizont stage was apparent after 8 h by thin blood smear. At
later time points, arrested schizonts showed signs of degradation.
Chlorotonil A acts quickly.The standard in vitro susceptibility
assay does not account for short drug pulses, but in vivo drug
concentrations fluctuate, and high concentrations aremaintained
for limited time periods only. Therefore, we incubated ring-stage
parasites with chlorotonil A or the comparator drugs (artesunate
and chloroquine) for 1 h, removed the drug, and continued incu-
bation as in the standard drug sensitivity assay. The IC50 of a 1-h
pulse of chlorotonil A was only 1.3 0.7-fold higher than that of
the standard assay. In contrast, the IC50 of a 1-h pulse of artesunate
was 15.6  9.1-fold higher than that of the standard assay. As
expected, chloroquine was not active when given as a short pulse
at the ring stage, even at the highest concentration tested
(160 M).
Chlorotonil A is active in vivo.Chlorotonil A is not soluble in
most commonly used solvents. Nevertheless, a pilot experiment to
assess the therapeutic efficacy of nonsolubilized orally adminis-
tered chlorotonil A was performed in P. berghei ANKA-infected
BALB/c mice and Swiss CD1mice using the Peters 4-day suppres-
sion test (31). The activity levels of chlorotonil A on day 4 were
97% in BALB/c mice and 98% in Swiss CD1 mice compared to
that of the control mice. On day 5, the antiplasmodial activity
levels were 93% (BALB/c) and 85% (Swiss CD1). However, the
cure was not complete with the standard protocol, as none of the
mice were cleared of their parasitemia completely (Fig. 3). In
BALB/c mice, all the doses (36, 68, and 110 mg/kg) resulted in a
substantial reduction of parasitemia. This reduction showed some
dose dependency; however, due to the small sample size, this was
not analyzed formally. The mice did not show obvious signs of
toxicity due to chlorotonil A treatment at either dose.
Chlorotonil A is active against gametocytes. To assess the ac-
tivity of chlorotonil A against stage IV to V gametocytes, we used
TABLE 1 Inhibitory concentrations of tested compounds against P.
falciparum strains 3D7 and Dd2a
Compound
IC (meanSD) (nM) of indicated compound for strain:
3D7 Dd2
IC50 IC90 IC50 IC90
Chlorotonil A 9.1 3 13.34 3.2 18.1 8.6 28.5 8.5
Chloroquine 5.2 1.2 8.2 2.3 160.4 62.1 228.6 66.4
Artesunate 2.4 1.3 7.5 4.6 1.3 0.2 1.8 0.2
a Each value is the mean inhibitory concentration of at least 3 independent experiments
performed in duplicate.
TABLE 2 Median inhibitory concentrations of 25 (chlorotonil A and
chloroquine) and 26 (artesunate) different clinical isolates against the
indicated compoundsa
Compound
IC50 (median
[range]) (nM)
IC90 (median
[range]) (nM)
Chlorotonil A 15.2 (3.7–32) 37.1 (6.8–76.2)
Chloroquine 47.2 (19.5–117) 111.6 (44.2–191.1)
Artesunate 0.6 (0.2–3.2) 1.8 (0.6–4.7)
a Each experiment was performed once.
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an in vitro bioluminescence assay (32). Chlorotonil A was active
against late-stage gametocytes at concentrations similar to those
against asexual blood stages. This is in contrast to artesunate and
dihydroartemisinin, which act only when used in very high con-
centrations (Table 3). Epoxomicin served as an internal control
for the assay, since it is known to be highly active against stage IV
to V gametocytes.
DISCUSSION
So far, continuous development of new drugs remains the only
option for keeping pace with the potential of P. falciparum to
adapt to manmade interventions. Myxobacteria, especially those
in the genus Sorangium, have proven to be a valuable source for
new chemotherapeutic compounds, such as soraphens, soran-
gicins, thuggacins, and epothilones (35–37), some of which are in
advanced preclinical and clinical development. For example, ixa-
bepilone (BMS-247550), an analogue of epothilone B, was ap-
proved by the Food and Drug Administration in 2007 for the
treatment of breast cancer (38). Sorangium cellulosum strain So
ce1525 was identified as our main producer of chlorotonil A and
yields several natural products exhibiting different chemical scaf-
folds. New scaffolds are of particular interest for the development
of new antimalarials, since most compounds in the development
pipeline belong to a restricted number of drug classes.
Chlorotonil A shows several remarkable features which char-
acterize it as a promising lead compound. Apart from being active
against chloroquine-sensitive and chloroquine-resistant strains at
low nanomolar concentrations, it acts against all blood stages of
themalaria parasite and does not show a hysteresis effect, which is
a characteristic of several antimalarial antibiotics (39, 40). Chlo-
rotonil A acts against early in the ring and trophozoite stages of the
parasite and is therefore able to reduce parasite biomass and
the generation of parasite toxins immediately upon contact with
the parasite (41). This is notable since it is one characteristic that
needs to be fulfilled by drug candidates for the treatment of severe
malaria; also, artemisinin derivatives have a similar profile of ac-
tion. The mode of action of chlorotonil A is not known, but the
loss of activity observed for the dehalogenated derivative points
FIG 2 Stage-specific inhibition of P. falciparum by chlorotonil A. Giemsa-stained thin blood smears of synchronous ring (A), trophozoite (B), and schizont (C)
stages. Shown are P. falciparum 3D7 parasites after different incubation times (8, 24, and 40 h) with chlorotonil A and artesunate (ring and trophozoite stages)
and epoxomicin and artesunate (schizont stage) at the indicated concentrations compared to those of the drug-free control.
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toward an important role of the chlorine-containing pharmaco-
phore. It also acts against clinical isolates with a different genetic
background, isolated from patients in Lambaréné, Gabon, an area
of high-grade resistance against chloroquine and sulfadoxine-py-
rimethamine (42, 43). The lack of correlation with its comparator
drugs, chloroquine and artesunate, supports the assumption that
chlorotonil A has a different mechanism of action than that of
these two other drugs.
The first tests in the murine P. berghei model demonstrated
that chlorotonil A is active in vivo, has low toxicity, and can be
administered orally. Due to its poor solubility, it was given to the
mice as a powder together with peanut butter because tetrahydro-
furan, the solvent used for in vitro assays, is toxic for mice (44).
Currently, we are exploring alternative formulations and chemical
modifications to develop chlorotonil A from an early lead toward
a drug development candidate. In addition, it would be interesting
to test anthracimycin, a structural relative of chlorotonil A, and its
dichloro derivative (45).
An exceptional property of chlorotonil A is its very rapid onset
of action; 1 h of contact with the parasite is sufficient to exert its
full activity. The two comparator drugs, artesunate and chloro-
quine, had strongly reduced activity levels when pulsed for only 1
h. Rapid onset, as seen for chlorotonil A, is especially important
for drugs that are used to treat severe malaria, for which a rapid
reduction of the parasitemia level is vital for the survival of the
patient. In addition, rapid onset is important for drugs with a
short half-life, like artesunate and dihydroartemisinin. These two
drugs exhibit half-lives of1 h (46), and thus, the time span of the
therapeutic drug concentration above the antiparasitic threshold
is short. This is one of the reasonswhy the cure rates of artemisinin
derivatives are poor when given for5 to 7 days as monotherapy
(47). Its activity against late-stage gametocytes is an additional
valuable feature of chlorotonil A. Late-stage gametocytes are es-
pecially difficult to target by drugs. Until now, primaquine has
been the only licensed drug with known activity against them in
vivo, but its hemolytic effect in individuals with glucose-6-phos-
phate dehydrogenase deficiency limits its use (48). Artemisinin
derivatives decrease gametocyte carriage in vivo mainly by their
rapid action, accompanied by the reduction of parasite biomass,
but it has been shown that they cannot stop transmission com-
pletely (49, 50). The effect of artemisinin derivatives on gameto-
cytes is still under discussion; they probably also act against early
gametocytes, but only little activity against late-stage gametocytes
has been reported (32, 51–53). This is also in concordance with
our assay. Especially when compared side by side with chlorotonil
A, the activity level of artemisinin is orders of magnitude lower. A
new gametocytocidal drug would be a major step forward for the
feasibility of elimination and resistance containment campaigns,
especially in low-endemicity settings where transmission blocking
is crucial for finally stopping the cycle.
Chlorotonil A exhibits the promising characteristics of a po-
tential new lead compound, namely, its low toxicity, oral availabil-
ity, rapid onset of action, and activity against all erythrocytic stages
of the parasite. In addition, it is active against the transmission
stages of the parasite. Improved derivatives and dose regimens are
required prior to clinical development, but at this stage, it is al-
FIG 3 Parasitemia levels of P. berghei in chlorotonil A-treatedmice. Parasitemia levels in four P. berghei-infected BALB/c (balbc/1 to balbc/4) and five Swiss CD1
(swiss/1 to swiss/5) mice from day 1 (d1) to d5 in the 4-day suppression test. Mice indicated by black lines received either 36, 68, or 110 mg/kg (BALB/c) or 100
mg/kg (Swiss CD1) chlorotonil A, and mice indicated by the light-gray lines received placebo control.
TABLE 3 Inhibitory concentrations of tested compounds against stage
IV to V gametocytes of P. falciparum strain 3D7a
Compound
IC50 (mean SD)
(nM)
IC90 (mean SD)
(nM)
Chlorotonil A 29.6 16.3 123.2 36.9
Artesunate 8,917 4,830 25,852 19,563
Dihydroartemisinin 2,918 964 16,603 16,141
Epoxomicin 3.2 2.6 14.3 16.7
a Each value is the mean inhibitory concentration of at least 3 independent
experiments.
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ready evident that chlorotonil A has unique features that warrant
its further assessment.
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